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1 Introduction 
1.1 Gene therapy – a brief history 
Gene therapy holds much promise to treat or to prevent diseases by delivering therapeutic 
nucleic acids into patients, although the field has experienced intense criticism and 
skepticism within recent years.1,2 
 
The conceptually new approach to the treatment of human diseases using gene therapy 
arose during the 1960s and 1970s.3,4 At this point in time, the first evidences for uptake and 
expression of exogenous DNA in mammalian cells have been found. Since then, the 
concepts and techniques of gene therapy rapidly progressed and the idea that human 
genetic disorders, infections and some degenerative diseases may be amenable to 
correction at the genetic level has cleared from theoretical ideas and became practically 
more feasible (see Table 1). 
Table 1: List of significant points in the early development of gene therapy5 
 
However, after the severely, on both scientific and ethical ground, criticized first gene transfer 
study by Cline and colleagues in 19806-9, science, ethics and public policy aspects were 
Year Result Reference 
1960-70 Evidence of uptake 
and expression of 
exogenous DNA in 
mammalian cells 
Szybalska, E.H. and Szybalski, W.: Genetics of human cell lines IV. DNA-
mediated heritable transformation of a biochemical trait. PNAS (1962) 
 
Majumdar, A. and Bose, S.K.: DNA mediated genetic transformation of a 
human cancerous cell line in cultured in vitro. Ind. J. med. Res. (1968)  
1980-81 Cline human study Cline, M.J. et al.: Gene transfer in intact animals. Nature (1980) 
 
Mercola K.E., Stang, H.D., Browne, J. and Cline, M.J.: Insertion of a new 
gene of viral origin into bone marrow cells of mice. Science (1980) 
 
Kolata GB, Wade N.: Human gene treatment stirs new debate. Science 
(1980)  
 
Wade N.: Gene therapy caught in more entanglements. Science (1981)  
1980 Public discussion 
“Gene therapy in 
human beings: When 
is it ethical to begin?” 
Anderson WF, Fletcher JC.: Sounding boards. Gene therapy in human 
beings: when is it ethical to begin? N Engl J Med. (1980)  
1989-90 First approved human 
gene therapy trial 
Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, 
Karson EM, Lotze MT, Yang JC, Topalian SL, et al.: Gene transfer into 
humans--immunotherapy of patients with advanced melanoma, using 
tumor-infiltrating lymphocytes modified by retroviral gene transduction. N 
Engl J Med. (1990)  
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catalyzed and the question was no longer if human gene therapy can be developed, but 
rather how.10 In 1989, Rosenberg and his colleagues performed the first approved human 
gene therapy clinical trial using retroviruses to introduce the gene encoding for resistance to 
neomycin into human tumor-infiltrating lymphocytes prior to re-infusion into patients with 
advanced melanoma.11 This study demonstrated at first the feasibility of gene therapy using 
viral systems and set a basis for over 1300 clinical gene therapeutic trials that have been 
either completed, are still ongoing or are approved in 28 countries worldwide so far (2007).2  
 
Nevertheless, there have been a few regrettable cases of severe adverse effects after gene 
therapeutic treatment (unexpected inflammatory reaction to adenovirus vectors causing 
death or leukemia-like clonal lymphocyte proliferation related to retroviral chromosomal 
integration), which had an inevitable effect on the progress of and enthusiasm for the clinical 
implementation of gene therapy. This has prompted scientists to undertake more detailed 
investigations into the behavior of vector systems and encouraged them for more careful 
testing of various approaches and technologies to ameliorate the field, resulting in greater 
steps toward safe and efficient gene therapeutic applications in the future. 
 
The diseases targeted by gene therapy are various but the vast majority has addressed 
cancer, cardiovascular and inherited monogenetic diseases. While the different strategies 
applied in cancer gene therapy range from inserting tumor-suppressor genes, to 
immunotherapy and gene-directed enzyme prodrug therapy (GDEPT), cardiovascular gene 
therapy mainly addresses therapeutic angiogenesis by over expressing e.g. the fibroblast 
growth factor (FGF) or the vascular endothelial growth factor (VEGF). The aim in treating 
monogenic disorders is the permanent correction of the malfunctioning gene. Other 
indications addressed by gene therapy include human immunodeficiency virus (HIV) 
infections, tetanus and cytomegalovirus (CMV) infections as well as some neurological 
diseases, multiple sclerosis, glaucoma and age-related macular degeneration.2  
 
Nucleic acids transferred in clinical trials are genes encoding for antigens, cytokines, tumor-
suppressor or suicide genes, growth factors or different receptors while recently much 
interest has also sparked in RNA interference (RNAi) including especially the delivery of 
short interfering RNA (siRNA) for therapeutic application.2 
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1.2 Synthetic delivery systems for gene therapy 
An ideal gene carrier should protect the nucleic acid against nucleases and should deliver 
the payload efficiently and exclusively to the target site. Since the delivery of naked DNA is 
only successful when injected directly into the target tissues or cells, several gene 
transferring vectors have been developed to improve transfection efficiency. Generally, these 
delivery devices can be divided into two main categories: viral vectors and synthetic transfer 
systems. 
 
Viral vectors are the most commonly used gene transfer systems employed in clinical trials 
due to their high potency in gene transfer.1,2 The limitations associated with viral vectors in 
terms of safety, immunogenicity, low transgene loading size and high costs have encouraged 
researchers to focus on different alternatives: synthetic gene delivery systems. 
 
 
 
Fig. 1: Schematic representation of the different barriers that have to be overcome by a gene 
carrier system. After systemic application, polyplexes have to survive in the bloodstream without 
being degraded or captured by cellular immunogenic defense mechanisms (e.g. complement 
system). At the tumor site they have to extravasate into the tissue and bind – ideally – specifically to 
the target cell. After internalization, additional intracellular hurdles appear, such as endosomal 
escape, cytoplasmic trafficking and nuclear import. 
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The limitations of viral vectors, in particular their safety concerns, render synthetic vectors as 
alternatives progressively interesting. Moreover, they offer an enhanced biosafety profile 
since they can be generated protein-free or by only non-immunogenic or humanized 
proteins/peptides resulting in lower immunogenicity. A further benefit of synthetic transfer 
systems is that they can easily be synthesized in large quantities at rather low cost and offer 
a higher loading capacity for DNA. However, the major drawback of synthetic vectors is their 
limited efficacy compared to viral vectors after in vivo application, which is currently mainly 
compensated by the application of larger quantities of vector formulation. 
 
Most synthetic vectors are generally based on formulations of chemically defined, positively 
charged polymers (polycations or cationic lipids), which interact electrostatically with the 
negatively charged nucleic acids. The resulting “polyplexes” or “lipoplexes” protect DNA from 
degradation and are positively charged themselves due to an excess of polymer used to form 
compact nano-sized complexes suitable for cell entry. Cell entry mainly occurs due to 
interactions with the negatively charged cell membranes and polyplexes are endocytosed 
afterwards (see Fig. 1). 
 
It is quite obvious that no polymer is able to meet all of these requirements. Thus, it is often 
necessary to generate a so called “synthetic virus” system consisting of a cationic 
compacting part in combination with various functional domains in order to meet all 
demands.  
 
1.3 Polymers used as synthetic vectors 
Over the last decades a huge variety of polymers, mainly cationic polymers or cationic lipids 
have been investigated to generate synthetic gene carriers. The following section will focus 
on cationic polymeric compounds that were recently developed for systemic gene delivery. 
For cationic lipids as delivery vectors see the review by Li and Szoka (2007).12 
 
To date, systemic administration of polycationic polymers often resulted in a toxic response, 
which is mostly linked to the positive surface charge of the vectors making them incompatible 
for large clinical applications. Therefore, the main objective in gene therapy for systemic 
administration is the development of stable and non-toxic gene vectors that can compact and 
deliver genetic materials into specific cell types exhibiting transfection efficiencies 
comparable to viral vectors under physiological conditions. The existing synthetic cationic 
systems can be divided into two groups: non-degradable and degradable polymers. 
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1.3.1 Non-degradable polymers – polyethylenimines (PEI) 
PEI can be synthesized at various molecular weights, in a branched or linear manner or can 
undergo functionalization by group addition or substitution. PEI is the most commonly used 
polycation and has a privileged place in the line of synthetic gene delivery devices due to its 
superior transfection efficiency in a broad range of cell types compared to other systems. As 
PEI is able to form stable nano-scaled, positively charged polyplexes with DNA molecules, it 
is capable to enter cells after cell adhesion, followed by endocytosis and can promote its 
efficient escape from the endo-/lysosomal compartment by the so called “proton sponge 
effect”.13  
 
Studies showed that linear PEI (LPEI) with a molecular weight of 22 kDa is the most potent 
polycationic transfection agent and is thus defined as the “golden standard” for efficient in 
vitro gene delivery. Its excellent transfection/cytotoxicity–relation is much better compared to 
its branched PEI (BPEI) counterpart in a similar molecular weight range (25 kDa). However, 
the huge amount of positive surface charges14, the non-degradability of the polymer and a 
variety of undesired, unspecific interactions with the biological environment15,16 results in a 
fairly high toxicity of PEI polyplexes after systemic administration in vivo no matter whether a 
linear or a branched conjugate is used.17,18  
 
1.3.2 Degradable polymers 
Non-degradable polymers like LPEI or BPEI are “static” structures, which cannot be 
degraded, metabolized and eliminated by the body. In consequence they can accumulate in 
cells or organs (mainly in excretion organs like liver or kidney) leading to undesired and 
uncontrollable long-term toxicity in living systems. Consequently, there is the urgent need for 
biodegradable polymers. Their potential advantages should be their reduced toxicity 
(provided that degradation products result in non-toxic compounds) and the avoidance of 
accumulation. Furthermore, the polymer degradation pattern could also be used to improve 
the intracellular release of the nucleic acid payload in order to enhance the desired 
therapeutic effect. 
 
The importance of using degradable polymers for gene delivery has been particularly 
recognized within the last years. Naturally occurring polymers like chitosans19 or their 
derivatives20-23 as well as peptidic polymers like poly(L-lysine) (PLL)24-26 or the PLL analogue 
poly (α-[4-amino-butyl]-L-glycolic acid) (PAGA)27-29 are biodegradable and therefore possess 
an advantage in terms of their toxicity profile for in vivo application exhibiting a better 
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biocompatibility compared to PEIs.30 However, for example in case of PLL, although low 
molecular weight (LMW) compounds have been found to result in a strongly reduced toxicity 
compared to their high molecular weight (HMW) counterparts, they do not present a sufficient 
stability of the formed polyplexes under physiological conditions. Consequently, they are 
rapidly removed from the blood circulation e.g. by Kupffer cells in the liver.26,31,32 Other non-
toxic and easily excretable LMW polyamines like e.g. the naturally occurring spermine      
(Mw 202 Da) or spermidine (Mw 145 Da) as well as oligoethylenimines (e.g. OEI, 800 Da) 
exhibit the same effect of a low complex stability under physiological conditions and cannot 
be used as gene transfer agents.33 Hence, the main goal in the design and development of 
degradable polymers is to obtain polymers that show high extracellular stability of the formed 
polyplexes while, importantly, these should be easily destabilized intracellularily in order to 
release their nucleic acid payload efficiently while a low acute and long-term toxicity should 
be maintained. 
 
In Fig. 2 one approach to reach this goal is shown. The reversible oligomerization of LMW 
oligocations by crosslinking them with biodegradable linkers was already successfully shown 
by several researchers.31,34-37 Alternatively, degradable polymers could also be synthesized 
de novo by the addition of labile bonds within the repetitive monomeric units during 
synthesis. 
 
Fig. 2: Reversible oligomerization of low molecular weight oligoamines using degradable 
crosslinkers. Low molecular weight (LMW) oligoamines are crosslinked via reversible linkers to form 
oligomerized polyamines, which are capable to form stable polyplexes protecting DNA from 
degradation by nucleases. In a time- and/or environment-specific manner the labile bonds can be 
degraded in order to release the DNA resulting in non-toxic monomers that can easily be eliminated. 
(adopted from PhD thesis of Julia Kloeckner) 
 
Reversible linkages may include degradable bonds that break down due to enzymatic or 
chemical degradation (see Fig. 3). Hence, most of the degradable polymers contain 
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hydrolytically sensitive bonds including e.g. esters, acetals or hyrdazones. The use of 
disulfide bonds which are cleaved in the reductive intracellular environment has also been 
investigated by several groups.  
 
Fig. 3: Overview on different degradable bonds. Hydrolyzable bonds include ester, amide, acetal, 
ketal and hydrazone bridges, whereas disulfide bonds are degraded under reductive environment. 
 
In order to deliver and release the DNA efficiently, the gene carrier should be constructed in 
a way that uses the properties of the target site, to get triggered at the “right” point in time 
(e.g. by the presence of enzymes, pH, redox potential, etc). Moreover, the polymers should 
be degraded within one or a few days in order to reduce the potential accumulation at 
undesired sites. 
 
1.3.3 Dendrimers  
A technical weakness many of the synthesis approaches described above share is the 
polydispersity, i.e. the heterogeneity in molecular weight, which is inherent to the procedure 
of the applied random polymer synthesis. The design of dendrimers is an elegant solution to 
obtain well-defined conjugates with narrow molecular weight distribution. Dendrimers (from 
the Greek dendron: “tree” and meros: “part”) are spherical, highly branched structures that 
have a hierarchical, three-dimensional design. The core of the molecule provides a central 
point from which monomers ramify in well-ordered and symmetrical manner. The tree-like 
construction is created by repetition of the same sequence leading to a new dendrimer 
generation at the end of every reaction cycle.38 Currently, the preferred dendrimers are 
polyamines, polyamides and polyesters. As an example, polyamidoamine (PAMAM) 
dendrimers have already successfully been applied for gene delivery in vivo.39-41 
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1.4 Optimization of polyplexes toward “synthetic viruses” 
Even the most potent synthetic gene delivery devices can still not compete with viral vectors. 
Key issues for the optimization of polyplexes include an improved specificity for the target 
tissue, an accelerated intracellular and nuclear trafficking and in addition the already 
mentioned low toxicity of compounds. Furthermore, they should also provide good 
pharmacokinetic parameters. Hence, fundamental steps toward the ‘synthetic virus’ could 
only be achieved if the polyplexes were stable under physiological conditions, providing an 
increased specificity toward the target tissue and were able for an efficient overcome of  
most of the given cellular hurdles (see Fig. 1). Central steps to meet these goals are i) to 
imply methods to increase the colloidal stability of polyplexes under in vivo conditions and ii) 
to enhance their specificity toward the target site by introducing targeting ligands while a high 
biocompatibility of the gene delivering system should be maintained.  
 
1.4.1 Stabilization of polyplexes for in vivo application 
Despite their versatility and improved safety, synthetic gene delivery systems still lack high in 
vivo transfection efficiency. Therefore, developing a gene transfer system raises the 
challenge of finding solutions to efficiently deliver DNA to the target tissue (or target cell) but 
also being capable of effectively releasing the genetic payload for high gene expression. The 
low colloidal stability of polyplexes as well as possible unspecific interactions with blood 
components or proteins of the extracellular matrix are some of the reasons leading to 
hindrance of this property.15,42 Hence, an emerging theme in recent studies is the use of 
crosslinked, stabilized polyplexes to achieve an optimized balance between the stability of 
particles in the extracellular environment (e.g. in the bloodstream) and the controlled release 
of DNA within the cytosol of the target site.43,44 The idea of a transient, at best, bioreversibly 
triggered stabilization/destabilization strategy of polyplexes is quite favorable with regard to 
improving the pharmacokinetic properties of synthetic gene delivery devices. 
 
1.4.2 Targeting polyplexes for site-specific gene delivery 
Targeting – by definition – includes any strategy to improve the specificity of gene expression 
and/or the delivery of nucleic acids toward e.g. the tumor site, while highest transfection 
levels should be achieved. Multiple targeting methods have been investigated in the past 
including the targeted delivery of nucleic acids as well as transductional and transcriptional 
targeting strategies at the intracellular site of tumor cells (see Fig. 4). Transductional 
targeting comprises of all methods which improve the intracellular release and transport of 
transgenes toward the nucleus of the target cell. Triggered endosomal release, enhanced 
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cytosolic trafficking and the specific nuclear import of transgenes45 are the major objectives 
of this targeting policy. As soon as the genes are delivered into the nucleus they can only be 
expressed if adequate promoter and/or enhancer elements are included in the gene 
expression cassette. Transcriptional targeting utilizes tumor-specific promoter/enhancer 
systems resulting in specifically high levels of transcription controlled transgene expression. 
 
The cellular uptake of particle-based gene delivery systems usually occurs, as already 
mentioned, via charge-mediated interactions with the cell surface followed by endocytosis 
(see Fig. 1). Upon systemic administration, however, such non-specific interactions also take 
place with blood components and non-target tissues and hamper gene delivery. Specific 
delivery of polyplexes toward the tumor site can be mediated by physical (for review see 
Russ and Wagner, 2007)46 or biological targeting technologies. 
 
Biological targeting strategies toward the tumor site are achieved by taking advantage of the 
special tumor architecture and unique tumor properties. Basically, these strategies can be 
divided into two main groups: passive and active tumor targeting. The imperfect and leaky 
tumor vasculature, due to abnormal neovascularization required to serve fast-growing 
tumors, combined with an inadequate lymphatic drainage leads to passive targeting of 
polyplexes to the tumor site. This effect is termed “enhanced permeability and retention” 
(EPR effect)47. To exploit target cells specifically, gene delivering particles can be modified 
with numerous cell-targeting ligands such as peptides, proteins, vitamins and 
carbohydrates.46,48 All these ligands recognize specific receptors on the cell membrane of 
target cells bind specifically and result in receptor-mediated endocytosis of polyplexes (see 
Fig. 1). One commonly used ligand is the serum glycoprotein transferrin (Tf) using the 
 
Fig. 4: Tumor targeting principles for therapeutic nucleic acids. 
1 Introduction  10 
 
transferrin receptor (TfR) for targeted delivery. TfR required for iron uptake into cells is over-
expressed in tumor cells due to the higher demand of iron for their growth.49 Tf as protein 
ligand combines both a shielding function of the vectors and a targeting moiety toward the 
tumor site.50,51 It was found for example, that the incorporation of Tf or anti-Tf receptor single-
chain antibody Fv fragments into polyplexes and lipoplexes resulted in enhanced gene 
transfer efficiencies in vitro as well as in vivo.52-57  PEGylation of PEI/DNA polyplexes 
containing Tf as targeting ligand further improved the in vivo application. The epidermal 
growth factor (EGF) is another widely investigated ligand for tumor targeting58-61 as well as 
folate or several other proteins and peptides that target surface markers of for example 
endothelial cells including integrins like αvβ3 and αvβ5 or the CD 13 receptor.62   
 
 
1.5 Aim of the thesis 
The major focus in the development of novel degradable polymers for synthetic gene delivery 
– both for in vitro and in vivo gene delivery – is to synthesize highly efficient and low-toxic 
compounds. Up to now, many non-toxic and (bio-) degradable polymers have been 
generated. 
 
1.5.1 Design of novel pseudodendritic oligoamines for synthetic gene 
delivery 
The aim of this thesis was to develop a novel family of hyperbranched polymers, namely 
pseudodendrimers, which exhibit a better defined chemical structure compared to the 
randomly synthesized hitherto existing polycations (see Fig. 5). These compounds consist of 
a low molecular weight polycation (branched oligoethylenimine 800 Da (OEI) or 
polypropylenimine dendrimer (PPI)) in the center, functionalized with an excess of 
degradable dioldiacrylates to form a pseudodendritic core. The pseudodendritic core had to 
be subsequently modified on its surface with different oligoamines. Although these 
conjugates do not have the typical symmetric dendritic structure based on AB2 monomers, 
they follow the dendritic concept based on a branched structure, assembled by adding a 
generation of monomer to a core unit.38 
Used as gene delivery devices these pseudodendrimers may have several advantages: (i) 
amines, presented in the periphery of the pseudodendrimers can interact well with DNA and 
form nano-scaled pseudodendrimer / DNA complexes; (ii) the high density of secondary and 
tertiary amines within the polymer may facilitate endosomal escape of 
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pseudodendrimer / DNA complexes (“proton sponge” effect) inside the cell;13 (iii) the dendritic 
branches containing ester bonds allow degradation of pseudodendrimers under physiological 
conditions increasing their biocompatibility; (iv) pseudodendrimers can be easily modified on 
their surface to improve transfection efficiency or pharmacokinetic properties e.g. using 
crosslinkers for lateral stabilization of the polyplexes and/or  targeting ligands. 
 
Physicochemical and biological screening studies of several pseudodendrimers in vitro were 
planned to discover promising candidates for more detailed in vivo studies in tumor-bearing 
mice. 
 
Fig. 5: Pseudodendritic concept. Schematic illustration of the two steps in pseudodendrimer 
synthesis. In the first step, the pseudodendritic core is formed by an excess of dioldiacrylate and a 
low molecular weight oligoamine. Subsequently, the pseudodendritic core is modified upon its surface 
with different oligoamines as surface modification units. 
 
1.5.2 Establishment of a structure-activity relationship in vitro 
To elucidate what is needed for efficient DNA gene delivery using pseudodendrimers a study 
on their structure-activity relationship was performed using the OEI core based 
pseudodendrimers. Both the influence of the pseudodendritic core characteristics and the 
influence of the surface modification unit on transfection efficiency versus their cytotoxicity 
had to be investigated and were set into relation. A further aim was to unravel the reason 
why some polymers result in high gene expression at low cytotoxicity whereas others are 
characterized by a lack of transfection activity. Further requirements to achieve high 
transfection efficiency were investigated using PPI core based pseudodendrimers. 
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1.5.3 Gene transfer and biocompatibility studies in vivo 
The most promising degradable pseudodendrimers as found in in vitro studies had to be 
investigated for their in vivo transfection efficiency in a subcutaneous tumor model in mice. 
After studies regarding their biocompatibility, polyplexes were applied systemically. The 
transfection pattern in main organs and tumor tissue was examined finding predominant 
reporter gene expression in tumor tissue. Another aim was to improve the polyplex 
formulation of HD O particles to improve the reporter gene expression level. This had to be 
investigated by intratumoral application of polyplexes. 
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2 Materials and methods  
2.1 Chemicals and reagents 
Low molecular weight polyethylenimine 800 Da waterfree (oligoethylenimine, OEI), 1.6-
hexandioldiacrylate (HD), 1.4-butandioldiacrylate (BD), 1.2-ethyleneglycoldiacrylate (ED), 
branched PEI 25 kDa (BPEI), spermidine (Sp), spermine (S), ethylenediamine (EDA), 
triethylenetetramine (TETA), pentaethyleneheximine (PEHI), DAB-Am-8, polypropylenimine-
octaamine dendrimer, generation 2.0 (PPI G2) and DAB-AM-16, polypropylenimine-
hexadecaamine dendrimer, generation 3.0 (PPI G3) were purchased from SIGMA-Aldrich 
(Steinheim, Germany). PPI G2 and PPI G3 are also available from SyMO-Chem (Eindhoven, 
The Netherlands). Ethanolamine (E) was obtained from Fluka (Buchs, Switzerland). 
Polyethylenimine 1200 Da (O1200) and polyethylenimine 1800 Da (O1800) were from 
Polysciences Inc. (Warrington, PA). Linear PEI 22 kDa (LPEI) was synthesized by acid-
catalysed deprotection of poly(2-ethyl-2-oxazoline) (50 kDa, Aldrich) in analogous form as 
described63 and is also available from Polyplus Transfections (Strasbourg, France). All 
reagents were used without further purification. LPEI and BPEI were adjusted to pH 7 using 
1N HCl (SIGMA-Aldrich, Steinheim, Germany) prior to use. Dithiobis (succinimidylpropionate) 
(DSP) and disuccinimidyl suberate (DSS) were purchase from Thermo Fisher Scientific Inc. 
(Rockford, IL). 
 
Deuterium oxide (D2O) and dimethyl sulfoxide puriss. (DMSO) were purchased from SIGMA-
Aldrich (Steinheim, Germany). Water was used as purified, deionized water.  
 
Methylthiazolyldiphenyl-tetrazolium bromide (MTT) was obtained from SIGMA-Aldrich 
(Steinheim, Germany). Bafilomycin A1 was purchased from Alexis Biochemicals (Lausen, 
Switzerland). Luciferase cell culture lysis buffer 5 x reagents and D-luciferin sodium salt were 
obtained from Promega (Mannheim, Germany).  
 
Cell culture media, antibiotics and fetal calf serum (FCS) were purchased from Life 
Technologies (Karlsruhe, Germany). 
 
Plasmid DNA pCMVLuc for in vitro studies (Photinus pyralis luciferase under control of the 
CMV enhancer / promoter) described in Plank et al.64 was purified with the EndoFree 
Plasmid Kit from Qiagen (Hilden, Germany). pEGFPLuc as used for in vivo studies (a fusion 
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of enhanced green fluorescent protein (EGFP) and Photinus pyralis luciferase under control 
of the CMV enhancer / promoter) was obtained from Clontech Laboratories (Mountain View, 
CA) and was purified with the EndoFree Plasmid Kit from Qiagen (Hilden, Germany). 
pEGFP-N1 (Clontech) was produced and purified by ELIM Biopharmaceuticals (San 
Francisco, CA). 
2.2 Pseudodendrimer synthesis 
Pseudodendrimers were synthesized in two steps. In the first step, the pseudodendritic core 
was formed by Michael addition of low molecular weight branched oligoamines and an 
excess of dioldiacrylate. In the second step, the surfaces of the pseudodendritic cores were 
modified using a variety of oligoamines. 
 
2.2.1 Synthesis of OEI core based pseudodendrimers 
For the synthesis of the various OEI core based pseudodendrimers, polyethylenimine 800 Da 
waterfree (oligoethylenimine, OEI) was coupled with a 20-fold molar excess of three different 
dioldiacrylates. For this, OEI and dioldiacrylate stock solutions were prepared in anhydrous 
DMSO at concentrations of 0.1 M and 2 M, respectively. For surface modification each 
oligoamine stock solution was prepared at a concentration of 0.6 M in anhydrous DMSO. 
 
2.2.1.1 1.2-Ethyleneglycoldiacrylate (ED)-core conjugates 
100 µL OEI stock solution (0.01 mmol) was mixed with 800 µL anhydrous DMSO and 
subsequently 100 µL ED stock solution (0.2 mmol) was added. The reaction occurred at 
45 °C for 24 h under constant shaking (1000 rpm, Eppendorf Thermomixer). The resulting 
mixture was used for further synthesis without isolation of the product. The ED core was 
modified with different oligoamines including ethanolamine (E), spermidine (Sp), spermine 
(S) and OEI (O) by adding 0.3 mmol of each oligoamine stock solution (0.5 mL) to the 
reaction mixture. Reaction proceeded for 24 h at 22 °C under constant shaking (1000 rpm, 
Eppendorf Thermomixer). 
 
2.2.1.2 1.4-Butandioldiacrylate (BD)-core conjugates 
100 µL OEI stock solution (0.01 mmol) was mixed with 800 µL anhydrous DMSO and 
subsequently 100 µL BD stock solution (0.2 mmol) was added. The reaction occurred at 
45 °C for 24 h under constant shaking (1000 rpm, Eppendorf Thermomixer). The resulting 
mixture was used for further synthesis without isolation of the product. The BD core was 
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modified with different oligoamines including ethanolamine (E), spermidine (Sp), spermine 
(S) and OEI (O) by adding 0.3 mmol of each oligoamine stock solution (0.5 mL) to the 
reaction mixture. Reaction proceeded for 24 h at 22 °C under constant shaking (1000 rpm, 
Eppendorf Thermomixer). 
 
2.2.1.3 1.6-Hexandioldiacrylate (HD)-core conjugates 
100 µL OEI stock solution (0.01 mmol) was mixed with 800 µL anhydrous DMSO and 
subsequently 100 µL HD stock solution (0.2 mmol) was added. The reaction occurred at 
45 °C for 24 h under constant shaking (1000 rpm, Eppendorf Thermomixer). The resulting 
mixture was used for further synthesis without isolation of the product. The HD core was 
modified with different oligoamines including ethanolamine (E), ethylenediamine (EDA), 
spermidine (Sp), spermine (S) triethylenetetramine (TETA), pentaethyleneheximine (PEHI), 
OEI (O), oligoethylenimine 1200 Da (O1200) and oligoethylenimine 1800 Da (O1800) by 
adding 0.3 mmol of each oligoamine stock solution (0.5 mL) to the reaction mixture. Reaction 
proceeded for 24 h at 22 °C under constant shaking (1000 rpm, Eppendorf Thermomixer). 
 
2.2.2 Synthesis of PPI core based pseudodendrimers 
For the PPI core synthesis, polypropylenimine dendrimer generation 2 (G2), 
polypropylenimine dendrimer generation 3 (G3) and HD stock solutions were prepared in 
anhydrous DMSO at concentrations of 0.1 M, 0.045 M and 2 M, respectively. For surface 
modification units, OEI and G2 surface modification stock solutions were prepared at a 
concentration of 0.6 M in anhydrous DMSO. 
 
2.2.2.1 PPI dendrimer generation 2 (G2) core conjugates 
100 µL G2 stock solution (0.01 mmol) was mixed with 800 µL DMSO and subsequently 
100 µL HD stock solution (0.2 mmol) was added. The reaction occurred at 45 °C for 24 h 
under constant shaking (1000 rpm, Eppendorf Thermomixer). The resulting mixture was 
used for further synthesis without isolation of the product. Grafting the acrylate terminated 
cores proceeded for each oligoamine by adding 0.5 mL (0.3 mmol) of either OEI or G2 
surface modification stock solution to the reaction mixture. Reaction proceeded for 24 h at 
22 °C under constant shaking (1000 rpm, Eppendorf Thermomixer). 
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2.2.2.2 PPI dendrimer generation 3 (G3) core conjugates 
100 µL G3 stock solution (0.0045 mmol) was mixed with 800 µL DMSO and subsequently 
100 µL HD stock solution (0.2 mmol) was added. The reaction occurred at 45 °C for 24 h 
under constant shaking (1000 rpm, Eppendorf Thermomixer). The resulting mixture was 
used for further synthesis without isolation of the product. Grafting the acrylate terminated 
cores proceeded for each oligoamine by adding 1.1 mL (0.66 mmol) of either OEI or G2 
surface modification stock solution to the reaction mixture. Reaction occurred for 24 h at 
22 °C under constant shaking (1000 rpm, Eppendorf Thermomixer). 
 
2.2.3 Purification 
After synthesis, the obtained products were diluted 1:10 in water and the pH was 
immediately adjusted to pH 7 using 1N HCl. Purification was done via dialysis using a 
Spectra/Por® membrane (Spectrum Medical Industries, Inc, CA) against 4L of water at 4 °C 
for 24 h. In general a 1 kDa MWCO dialysis membrane was used for purification, except for 
the OEI core based pseudodendrimers modified with O1200 and O1800 as well as for G3 
PPI core derivatives where dialysis membranes with a MWCO of 3.5 kDa were used. Water 
was exchanged twice, i.e. after 2 h and 20 h of dialysis. The dialysates were freeze-dried. 
Yields of obtained products were listed as weight of product / weight of educts [w/w] percent.  
2.3 Pseudodendrimer characterization 
2.3.1 Structural analysis 
1H-NMR spectra were recorded in D2O on an Eclipse +500 spectrometer from JEOL, Tokyo, 
Japan operating at 500 MHz. 
 
ED E: 1H NMR (D2O): δ 4.2-4.5 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.8-3.9 (NCH2CH2OH, 
ethanolamine, 2H), δ 3.7 (HOCH2, mono-ester, 2H), δ 2.4-3.4 (82H NCH2CH2 of OEI ethylenes, NCH2CH2OH of 
ethanolamine, NCH2CH2COO linker) 
molar ratio (diacrylate / OEI) = 8.3 : 1; molar ratio (surface amine / OEI) = 1.5 
residual ester content after synthesis: 90% 
yield:  33% (weight of product / weight of educts [w/w] percent) 
 
ED Sp: 1H NMR (D2O): δ 4.2-4.5 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.8 (HOCH2, mono-
ester, 2H), δ 2.5-3.4 (88H NCH2CH2 of OEI ethylenes, NCH2CH2CH2NCH2CH2CH2CH2N of spermidine, 
NCH2CH2COO linker), δ 2.1 (NCH2CH2CH2NCH2CH2CH2CH2N, 2H, spermidine), δ 1.7-1.8 
(NCH2CH2CH2NCH2CH2CH2CH2N, 4H, spermidine) 
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molar ratio (diacrylate / OEI) = 6.3 : 1; molar ratio (surface amine / OEI) = 1.4  
residual ester content after synthesis: 88% 
yield:  26% (weight of product / weight of educts [w/w] percent) 
 
ED S: 1H NMR (D2O): δ 4.3-4.4 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.8 (HOCH2, mono-ester, 
2H), δ 2.4-3.4 (92H NCH2CH2 of OEI ethylenes, NCH2CH2CH2NCH2CH2- of spermine, NCH2CH2COO linker), δ 
2.1 (NCH2CH2CH2NCH2CH2-, 4H, spermine), δ 1.7 (NCH2CH2CH2NCH2CH2-, 4H, spermine) 
molar ratio (diacrylate / OEI) = 6.3 : 1; molar ratio (surface amine / OEI) = 2 
residual ester content after synthesis: 85% 
yield:  30% (weight of product / weight of educts [w/w] percent) 
 
ED O: 1H NMR (D2O): δ 4.2-4.4 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.8  (HOCH2, mono-
ester, 2H), δ 2.5-3.6 (80H NCH2CH2 of OEI ethylenes, NCH2CH2OH of ethanolamine, NCH2CH2COO linker) 
molar ratio (diacrylate / OEI) = 0.9*  (* ratio of diacrylate to total OEI (core plus surface OEI) 
residual ester content after synthesis: 71% 
yield:  30% (weight of product / weight of educts [w/w] percent) 
 
BD E: 1H NMR (D2O): δ 4.1-4.3 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.9 (NCH2CH2OH, 
ethanolamine, 2H), δ 3.6 (HOCH2, mono-ester, 2H), δ 2.5-3.4 (82H NCH2CH2 of OEI ethylenes, NCH2CH2OH of 
ethanolamine, NCH2CH2COO linker), δ 1.8 (COOCH2CH2, 4H di-ester, 2H mono-ester),δ 1.6 (2H HOCH2CH2 
mono-ester) 
molar ratio (diacrylate / OEI) = 8.6 : 1; molar ratio (surface amine / OEI) = 2.1 
residual ester content after synthesis: 94% 
yield:  32% (weight of product / weight of educts [w/w] percent) 
 
BD Sp: 1H NMR (D2O): δ 4.1-4.3 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.7 (HOCH2, mono-
ester, 2H), δ 2.5-3.4 (88H NCH2CH2 of OEI ethylenes, NCH2CH2CH2NCH2CH2CH2CH2N of spermidine, 
NCH2CH2COO linker), δ 2.1 (NCH2CH2CH2NCH2CH2CH2CH2N, 2H, spermidine),δ 1.9 
(NCH2CH2CH2NCH2CH2CH2CH2N, 4H, spermidine), δ 1.7-1.8 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.6 
(2H HOCH2CH2 mono-ester) 
molar ratio (diacrylate / OEI) = 8.1 : 1; molar ratio (surface amine / OEI) = 1.8 
residual ester content after synthesis: 88% 
yield:  24% (weight of product / weight of educts [w/w] percent) 
 
BD S: 1H NMR (D2O): δ 4.1-4.3 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-ester, 
2H), δ 2.5-3.4 (92H NCH2CH2 of OEI ethylenes, NCH2CH2CH2NCH2CH2- of spermine, NCH2CH2COO linker), δ 
2.1 (NCH2CH2CH2NCH2CH2-, 4H, spermine), δ 2.0 (NCH2CH2CH2NCH2CH2-, 4H, spermine), δ 1.7-1.8 
(COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.6 (2H HOCH2CH2 mono-ester) 
molar ratio (diacrylate/ OEI) = 9.6 : 1; molar ratio (surface amine / OEI) = 3.1 
residual ester content after synthesis: 94% 
yield:  38% (weight of product / weight of educts [w/w] percent) 
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BD O: 1H NMR (D2O): δ 4.1-4.2 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-ester, 
2H), δ 2.5-3.5 (80H NCH2CH2 of OEI ethylenes, NCH2CH2OH of ethanolamine, NCH2CH2COO linker), δ 1.7-1.8 
(COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.6 (2H HOCH2CH2 mono-ester) 
molar ratio (diacrylate / OEI) = 1.3*  (* ratio of diacrylate to total OEI (core plus surface OEI) 
residual ester content after synthesis: 85% 
yield:  25% (weight of product / weight of educts [w/w] percent) 
 
HD E: 1H NMR (D2O): δ 4.0-4.2 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.8-3.9 (NCH2CH2OH, 
ethanolamine, 2H), δ 3.6 (HOCH2, mono-ester, 2H), δ 2.4-3.4 (82H NCH2CH2 of OEI ethylenes, NCH2CH2OH of 
ethanolamine, NCH2CH2COO linker), δ 1.6-1.7 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5-1.6 (2H 
HOCH2CH2 mono-ester), δ 1.3-1.5 (-OCH2CH2CH2, 4H,  linker) 
molar ratio (diacrylate/ OEI) = 10 : 1; molar ratio (surface amine / OEI) = 3 
residual ester content after synthesis: 97% 
yield:  35% (weight of product / weight of educts [w/w] percent) 
 
HD EDA: 1H NMR (D2O): δ 4.1 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.5-3.6 (HOCH2, mono-
ester, 2H), δ 2.5-3.4 (84H NCH2CH2 of OEI and EDA ethylenes, NCH2CH2COO linker), δ 1.6-1.7 (COOCH2CH2, 
4H di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.3-1.4 (-OCH2CH2CH2, 4H,  linker) 
molar ratio (diacrylate / OEI) = 12 : 1; molar ratio (surface amine / OEI) = 8 
residual ester content after synthesis: 99% 
yield:  31% (weight of product / weight of educts [w/w] percent) 
 
HD Sp: 1H NMR (D2O): δ 4.1-4.2 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-
ester, 2H), δ 2.5-3.4 (88H NCH2CH2 of OEI ethylenes, NCH2CH2CH2NCH2CH2CH2CH2N of spermidine, 
NCH2CH2COO linker), δ 2.1 (NCH2CH2CH2NCH2CH2CH2CH2N, 2H, spermidine), δ 1.9 
(NCH2CH2CH2NCH2CH2CH2CH2N, 4H, spermidine), δ 1.6-1.7 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5 
(2H HOCH2CH2 mono-ester), δ 1.3-1.4 (-OCH2CH2CH2, 4H,  linker) 
molar ratio (diacrylate / OEI) = 11.4 : 1; molar ratio (surface amine / OEI) = 4.1 
residual ester content after synthesis: 98% 
yield:  40% (weight of product / weight of educts [w/w] percent) 
 
HD S: 1H NMR (D2O): δ 4.1-4.2 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-ester, 
2H), δ 2.5-3.5 (92H NCH2CH2 of OEI ethylenes, NCH2CH2CH2NCH2CH2- of spermine, NCH2CH2COO linker), δ 
2.1 (NCH2CH2CH2NCH2CH2-, 4H, spermine), δ 1.8 (NCH2CH2CH2NCH2CH2-, 4H, spermine), δ 1.6-1.7 
(COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.3-1.4 (-OCH2CH2CH2, 4H,  
linker) 
molar ratio (diacrylate / OEI) = 12.5 : 1; molar ratio (surface amine / OEI) = 6.5 
residual ester content after synthesis: 96% 
yield:  46% (weight of product / weight of educts [w/w] percent) 
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HD TETA: 1H NMR (D2O): δ 4.1 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.5-3.6 (HOCH2, mono-
ester, 2H), δ 2.4-3.4 (92H NCH2CH2 of OEI and TETA ethylenes, NCH2CH2COO linker), δ 1.6-1.7 (COOCH2CH2, 
4H di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.3-1.4 (-OCH2CH2CH2, 4H,  linker) 
molar ratio (diacrylate / OEI) = 12 : 1; molar ratio (surface amine / OEI) = 7.2 
residual ester content after synthesis: 97% 
yield:  16% (weight of product / weight of educts [w/w] percent) 
 
HD PEHI: 1H NMR (D2O): δ 4.1 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-ester, 
2H), δ 2.5-3.4 (100H NCH2CH2 of OEI and PEHI ethylenes, NCH2CH2COO linker), δ 1.6-1.7 (COOCH2CH2, 4H 
di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.3-1.4 (-OCH2CH2CH2, 4H,  linker) 
molar ratio (diacrylate / OEI) = 12 : 1; molar ratio (surface amine / OEI) = 6 
residual ester content after synthesis: 98% 
yield:  24% (weight of product / weight of educts [w/w] percent) 
 
HD O: 1H NMR (D2O): δ 4.1 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-ester, 
2H), δ 2.5-3.4 (80H NCH2CH2 of OEI 800 Da ethylenes, NCH2CH2COO linker), δ 1.7 (COOCH2CH2, 4H di-ester, 
2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.4 (-OCH2CH2CH2, 4H,  linker) 
molar ratio (diacrylate / OEI) = 1.4*  (* ratio of diacrylate to total OEI (core plus surface OEI) 
residual ester content after synthesis: 87% 
yield:  40% (weight of product / weight of educts [w/w] percent) 
 
HD O1200: 1H NMR (D2O): δ 4.1 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.6 (HOCH2, mono-
ester, 2H), δ 2.5-3.2 (188H NCH2CH2 of OEI 800 Da and OEI 1200 Da ethylenes, NCH2CH2COO linker), δ 1.7 
(COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.3-1.4 (-OCH2CH2CH2, 4H,  
linker) 
molar ratio (diacrylate / OEI) = 1.7*  (* ratio of diacrylate to total OEI (core plus surface OEI)residual ester content 
after synthesis: 88% 
yield:  62% (weight of product / weight of educts [w/w] percent) 
 
HD O1800: 1H NMR (D2O): δ 4.1 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester), δ 3.5 (HOCH2, mono-
ester, 2H), δ 2.5-3.4 (244H NCH2CH2 of OEI 800 Da and OEI 1800 Da ethylenes, NCH2CH2COO linker), δ 1.6-
1.7 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 mono-ester), δ 1.4 (-OCH2CH2CH2, 4H,  
linker) 
molar ratio (diacrylate / OEI) = 1.6*  (* ratio of diacrylate to total OEI (core plus surface OEI)residual ester content 
after synthesis: 79% 
yield:  50% (weight of product / weight of educts [w/w] percent) 
 
G2-HD-OEI: 1H NMR (D2O): δ 4.0 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester),  δ 3.5 (HOCH2, mono-
ester, 2H), δ 2.5-3.4 (136H  NCH2 of OEI ethylenes, NCH2CH2CH2 of PPI propylenes, NCH2CH2COO linker), δ 
1.7-2.0 (28H of NCH2CH2CH2 of PPI propylenes), δ 1.6 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5 (2H 
HOCH2CH2 mono-ester); δ 1.35 (4H –OCH2CH2CH2 linker). 
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molar ratio (diacrylate / PPI) = 8 : 1; molar ratio (surface amine / PPI) = 7 
residual ester content after synthesis: 79% 
yield:  32% (weight of product / weight of educts [w/w] percent) 
 
G2-HD-G2: 1H NMR (D2O): δ 4.0 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester),  δ 3.5 (HOCH2, mono-
ester, 2H), δ 2.8-3.4 (64H NCH2CH2CH2 of PPI propylenes, NCH2CH2COO linker), δ 1.65-2.2 (28H of 
NCH2CH2CH2 of PPI propylenes), δ 1.65 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.5 (2H HOCH2CH2 
mono-ester); δ 1.35 (4H –OCH2CH2CH2 linker). 
molar ratio (diacrylate / PPI) = 1.3 : 1*  (* ratio of diacrylate to total PPI (core plus surface PPI) 
residual ester content after synthesis: 88% 
yield:  62% (weight of product / weight of educts [w/w] percent) 
 
G3-HD-OEI: 1H NMR (D2O) : δ 4.0 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester),  δ 3.5 (HOCH2, mono-
ester, 2H), δ 2.5-3.3 (200H  NCH2 of OEI ethylenes, NCH2CH2CH2 of PPI propylenes, NCH2CH2COO linker), δ 
1.75-2.1 (60H of NCH2CH2CH2 of PPI propylenes), δ 1.65 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.55 (2H 
HOCH2CH2 mono-ester); δ 1.4 (4H –OCH2CH2CH2 linker). 
molar ratio (diacrylate / PPI) = 16 : 1; molar ratio (surface amine / PPI) = 11 
residual ester content after synthesis: 83% 
yield:  41% (weight of product / weight of educts [w/w] percent) 
 
G3-HD-G2: 1H NMR (D2O) : δ 4.0 (COOCH2, ester linker, 4H, di-ester, 2H, mono-ester),  δ 3.5 (HOCH2, mono-
ester, 2H), δ 2.5-3.3 (184H NCH2CH2CH2 of PPI propylenes, NCH2CH2COO linker), δ 1.75-1.9 (88H of 
NCH2CH2CH2 of PPI propylenes), δ 1.65 (COOCH2CH2, 4H di-ester, 2H mono-ester), δ 1.55 (2H HOCH2CH2 
mono-ester); δ 1.4 (4H –OCH2CH2CH2 linker). 
molar ratio (diacrylate / PPI) = 1.5 : 1*  (* ratio of diacrylate to total PPI (core plus surface PPI) 
residual ester content after synthesis: 68% 
yield:  23% (weight of product / weight of educts [w/w] percent) 
 
2.3.2 Molecular weight determination 
Molecular weights were determined by gel permeation chromatography (GPC). GPC analysis 
was performed using an Agilent 1200 series HPLC system (Morges, Switzerland) equipped 
with a refractive index detector, a NOVEMA 10 µm precolumn and a NOVEMA 300 analytical 
column (10 µm, 8x300 mm) (PSS, Mainz, Germany). The mobile phase was maintained in 
formic acid and sodium chloride (0.1% (V/V) HCOOH, 0.1 M NaCl, pH 2.8) at a flow rate of 
1 mL/min. 10 µL of methanol were added to 1 mL of sample (5 mg/mL) as internal standard. 
Results were evaluated using PSS WinGPC Unity software. Molecular weights were 
measured relative to Pullulan molecular weight standards that were used for preparing a 
standard calibration curve.  
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2.3.3 Degradation of pseudodendrimers 
Hydrolysis of selected pseudodendrimers was investigated in an aqueous solution 
(10 mg/mL, 1 mL, D2O) at pH 7 at 37 °C using 1H NMR spectroscopy to determine the 
decrease of ester bonds (Eclipse +500 spectrometer, JEOL, Tokyo, Japan operating at 
500 MHz). Remaining ester content was expressed as a percent relative to ester content 
determined after synthesis (t = 0d). 
 
2.4 Physicochemical characterization of polymers and polyplexes 
2.4.1 DNA binding ability 
The ability of pseudodendrimers to bind DNA reduces DNA intercalation of ethidium bromide 
(EtBr). As only intercalated EtBr results in strong fluorescence (λex= 510 nm, λem= 590 nm)65, 
the DNA condensation can be expressed as relative fluorescence intensities to plain DNA, 
which results in 100% fluorescence intensity (% rel. F.= Fpolyplex / Fplain DNA). Fluorescence was 
measured using a Cary Eclipse fluorescence spectrophotometer (Varian Deutschland GmbH, 
Darmstadt, Germany).  
EtBr was diluted in either HEPES-buffered glucose (HBG, 5% [w/w] glucose, 20 mM HEPES, 
pH 7.1) or HEPES-buffered saline (HBS, 20 mM HEPES, 150 mM NaCl, pH 7.1) to a final 
concentration of 0.4 µg/mL. 2 mL of EtBr dilution were mixed with 20 µg of plasmid DNA and 
fluorescence intensity was measured after 3 minutes. Polycation was added stepwise every 
20 seconds and % rel. F. was determined as described above.  
 
2.4.2 Polyplex formation 
Plasmid DNA was condensed with polymers at indicated conjugate / plasmid ratios (c/p-ratio) 
[weight/weight]. In general, HBG was used for polyplex formation unless otherwise indicated. 
In brief, polyplexes were prepared by adding the polymer solution at varying concentrations 
to DNA solution. Polyplexes were allowed to incubate for 20 min at room temperature prior to 
use.  
 
2.4.3 Agarose gel retardation  
Polyplexes were prepared as indicated in the corresponding experimental settings at a final 
DNA concentration of 20 µg/mL. 10 µL of complex mixed with loading buffer was loaded on a 
0.8% agarose gel in TBE buffer containing ethidium bromide. The gel was run at 100 V for 
1 h and then photographed under UV light. 
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2.4.4 Stability of complexes against sodium chloride 
The stability of polyplexes to an increasing amount of sodium chloride was studied using a 
Cary Eclipse fluorescence spectrophotometer (Varian Deutschland GmbH, Darmstadt, 
Germany) at λex = λem = 600 nm following a procedure as described by Oupický et al..66 A 
significant reduction of scattering signal was attributed to dissociating complexes. Briefly, 
aliquots of 5 M NaCl were added to 2 mL of polyplex solution (10 µg/mL DNA; in HBG) and 
changes in the intensity of scattered light were followed. 
 
2.4.5 Particle size measurement and zeta-potential determination 
Particle size and zeta-potential measurements of polyplexes were performed in HBG or HBS 
using a Zetasizer Nano ZS (Malvern Instruments, Herrenberg, Germany) equipped with a 
4 mW He-Ne laser at a wavelength of 633 nm at 25 °C. Scattered light was detected at a 
173° backward scattering angle. The viscosity and refractive index of water at 25 °C was 
used for data analysis. Polyplexes of different c/p-ratios had a final DNA concentration of 
10 µg/mL. Experiments were performed in a folded capillary cell (Malvern Instruments, 
Herrenberg, Germany). Dispersion Technology Software 5.0 (Malvern Instruments, 
Herrenberg, Germany) was used for data acquisition and analysis. 
2.5 Biological properties of pseudodendrimers in vitro 
2.5.1 Cell culture 
All cultured cells were grown at 37 °C in 5% CO2 humidified atmosphere. B16F10 murine 
melanoma cells (kindly provided by I. J. Fidler, Texas Medical Center, Houston, TX, USA) 
and murine neuroblastoma Neuro2a cells (ATCC CCI-131) were cultured in DMEM (1 g/l 
glucose) supplemented with 10% FCS. K562 (human chronic myeloid leukemia cells in blast 
crisis) were kindly provided by S. Kochanek, University of Ulm, Germany.  Human prostate 
adenocarcinoma cells, PC3 (DSMZ No ACC 465), were purchased from the german 
collection of microorganisms and cell cultures (DSMZ). The latter cell lines were cultured in 
RPMI 1640 growth medium supplemented with 10% FCS and antibiotics. 
2.5.2 Cytotoxicity of plain pseudodendrimers 
Neuro2a cells were seeded at a density of 1x104 cells in a 96-well plate in 200 µL medium 
(TPP, Transdingen, Switzerland). After 24 h, medium was replaced by 100 µL of fresh 
medium containing predetermined pseudodendrimer concentrations of 0.01 mg/mL to 
1 mg/mL. Per well, 50 µL samples were collected after an incubation time of 4 h and lactate 
dehydrogenase (LDH) concentration was determined using a commercial kit (Promega, 
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Cytotox 96, Madison, WI, USA) following the manufacturer’s protocol. The percent of LDH 
release was defined by the ratio of determined LDH concentration per well over total LDH 
content in untreated (intact) cells.  
Remaining 50 µL of medium per well were used to analyze the ATP content utilizing a 
commercial kit (Promega, Cell Titer Glo Luminescent Viability Assay, Madison, WI, USA) for 
the determination of ATP following the manufacturer’s protocol. The relative metabolic 
activity was defined by the ratio of measured ATP content over the ATP content of untreated 
cells.  
 
2.5.3 Luciferase reporter gene expression studies 
For screening transfection experiments (e.g. for OEI core based pseudodendrimers) the 
determination of reporter gene expression (firefly luciferase, pCMVLuc) was carried out in 
96-well plates (TPP, Transdingen, Switzerland). LPEI and BPEI polyplexes at their optimized 
c/p-ratio of 0.8 (representing an N/P-ratio of 6) were prepared as references.18 
In a standard experiment, 24 h prior to transfection B16F10 cells were seeded at a density of 
5x103 cells and Neuro2a cells at a density of 1x104 cells in 200 µL medium per well. For 
studies involving PC 3 cell a cell density of 5x103 cells was used. Transfections in K562 cells 
were performed in a 48-well plate (NUNC, flat bottom, Denmark) at a seeding density of 
12.5x104 cells per well. At the time point of transfection cells reached a confluency of 60% to 
80%. Before cells were treated with complexes, medium was exchanged against 100 µL 
fresh medium containing 100 U/mL penicillin and 100 µg/mL streptomycin. 10 µL of 
complexes were added directly to the cells and after 4 h medium was exchanged against 
100 µL fresh one. Transfection efficiency was evaluated 24 h after treatment. Cells were 
washed once with phosphate-buffered saline (PBS) and were subsequently lysed with 50 µL 
per well of 1:10 diluted cell culture lysis reagent (Promega, Mannheim, Germany). Luciferase 
activity was determined from 20 µL samples of the lysates using the Luciferase Assay 
system (Promega) at the luminometer (Lumat LB 9507, Berchtold, Germany). Two 
nanograms of recombinant luciferase (Promega, Mannheim, Germany) correspond to 107 
light units. Values are given as relative light units (RLU) per seeded cells (mean +/- standard 
deviations of at least triplicates) or as relative light units (RLU) per mg protein. 
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2.5.4 Enhanced green fluorescent protein (EGFP) gene expression 
studies 
EGFP expression studies were carried out in Neuro2a cells in a 24-well plate (NUNC, flat 
bottom, Denmark). 24 h prior to transfection 4x104 cells were plated in 1 mL of medium 
reaching a confluency of 60 to 80% at the point of time of transfection. Transfection of HD O, 
LPEI and BPEI polyplexes at their optimized c/p-ratios (in HBS) was performed using 1 µg of 
pEGFP-N1. 24 h after transfection, cells were viewed on an Axiovert 200 inverted 
fluorescence microscope (Carl Zeiss, Jena, Germany) equipped with an Axiocam camera 
using appropriate filters for EGFP excitation and emission. Digital image recording and 
image analysis were performed with the Axiovision 3.1 (Zeiss) software. For analysis of 
EGFP expression, cells were washed with PBS and harvested by trypsin treatment and 
analyzed using a CyanADP flow cytometer (DakoCytomation, Copenhagen, Denmark). Per 
sample, 3x104 gated events were collected. Values shown are the average of four 
transfected wells. Mean fluorescence intensities (MFI) and the percent of transfected cells 
are indicated in the pictures. 
 
2.5.5 Metabolic activity of transfected cells after polyplex treatment 
The percent of metabolic activity of cells after complex treatment was evaluated 24 h after 
transfection using the methylthiazoletetrazolium/thiazolyl blue (MTT) assay. To each well 
10 µL of a 5 mg/mL solution of MTT in sterile PBS buffer were added. Cells were incubated 
at 37 °C for 2 h, medium was completely removed and the samples were frozen at -80 °C for 
at least 1 h. 100 µL of DMSO was added and samples were incubated at 37 °C for 30 min 
under constant shaking. Optical absorbance was measured at 590 nm (reference wavelength 
630 nm) using a microplate plate reader (Spectrafluor Plus, Tecan Austria GmbH, Grödig, 
Austria). Metabolic activity was expressed relative to the MTT value for untreated cells taken 
as 100% metabolic activity of cells.  
 
2.5.6 Determination of total protein content 
For quantification of total protein concentration per well a bicinchoninic acid (BCA) assay kit 
(Pierce, Rockford, IL) was used. 25 µL of cell lysate were transferred to a 96-well plate 
(NUNC, flat bottom, Denmark) and 5 µL of a 0.1 M iodacetamide (in water) was added for 
inactivation of DTT.67 After 30 min of incubation at 37 °C, 200 µL of BCA working reagent 
were added following the manufacturers´ protocol. Optical absorbance was determined at 
590 nm after 30 min of incubation at 37 °C. Bovine serum albumin (BSA) was used as 
standard. 
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2.5.7 Hemolytic activity of polymers 
Freshly collected citrate buffered human blood was washed by four centrifugation cycles, 
each at 2200 rpm for 10 min at 4 °C with phosphate-buffered saline (PBS). Erythrocytes 
were resuspended in HBG / 10% FCS at a concentration of 4% (V/V). The suspension of red 
blood cells was always freshly prepared and used within 24 h. 75 µL of serial LPEI, BPEI and 
pseudodendrimer dilutions prepared in HBG / 10% FCS were mixed with 75 µL erythrocyte 
suspension in a 96-well plate (NUNC, V-bottom, Denmark). After 45 min at 37 °C under 
constant shaking, blood cells were removed by centrifugation (2200 rpm, 10 min, 4 °C) and 
80 µL of the supernatant was transferred to a new 96-well plate. Hemoglobin absorption was 
determined at 405 nm using a microplate reader (Spectraflour Plus, Tecan Austria GmbH, 
Grödig, Austria). HBG/10% FCS and a 1% Triton-X100 solution in PBS were used as 
negative and positive controls, respectively. 
Hemolysis is defined as percent (ODpolymer – ODbuffer / ODTriton-X100 – ODbuffer) *100. 
 
2.5.8 Polymer-induced erythrocyte aggregation 
The erythrocyte pellets were resuspended in 100 µL HBS for microscopic investigation and 
transferred to a 24-well plate (NUNC, flat bottom, Denmark) containing 1 mL HBS per well. 
Pictures were taken with a 20-fold magnification on an Axiovert 200 inverted fluorescence 
microscope (Carl Zeiss, Jena, Germany) equipped with an Axiocam camera. 
 
2.6 Stabilization and targeting of ester-degradable polyplexes 
2.6.1 Formation of stabilized HD O / DNA polyplexes via DSP or DSS 
HD O / DNA polyplexes were prepared at a c/p-ratio of 1 [w/w]. For comparative studies 
polyplexes of standard branched polyethylenimine BPEI (25 kDa) were prepared at a c/p-
ratio of 0.8 (representing an N/P-ratio of 6). Complex formation was performed in HBG by 
adding the appropriate amount of polycation to DNA solution. Polyplexes were allowed to 
incubate for 15 min at room temperature. The lateral stabilization of HD O or BPEI 
polyplexes was achieved by adding different amounts of DSP or DSS (1 mM solution in 
DMSO) to the prepared polyplexes for crosslinking. Polyplexes were then allowed to 
incubate for further 30 minutes to form surface crosslinks. The indicated different ratios of 
crosslinker applied are reported as a molar ratio between crosslinking agent (DSP or DSS) 
and HD O or BPEI amine groups, respectively; assuming that HD O contains 54 amines per 
molecule and BPEI 580 amines per molecule.68 The amount of amines for HD O was 
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calculated from 1H NMR data assuming that only the primary amines of the surface OEIs are 
accessible for crosslinking reactions via DSP or DSS. 
 
2.6.2 Formation of transferrin (Tf)-coated HD O / DNA polyplexes 
After formation of laterally stabilized polyplexes via DSP using a crosslinker / amine ratio of 
0.05 and incubation for 30 minutes, 3.5% (weight (Tf) / weight (HD O) ) transferrin in its pure 
and unoxidized form (Tfunox) or as oxidized transferrin (Tfox) (0.1 mg/mL in HBG) was added 
to form Tf–coated polyplexes. The transferrin solutions were supplemented with Fe citrate 
prior to use. Coated polyplexes were allowed to stand for additional 30 minutes prior to use. 
 
2.7 In vivo studies in mice 
2.7.1 In vivo gene transfer 
Animal experiments were performed according to guidelines of the German law of protection 
of animal life and were approved by the local animal experiments ethical committee. 
 
Male and female A/J mice were purchased from Harlan Winkelmann (Borchen, Germany) 
and housed in individually vented cages; food and water were provided ad libitum. For 
transfection studies 6-week-old mice were inoculated subcutaneously in the flank with 1x106 
Neuro2a cells. Experiments started when tumors reached diameter of 6 to 12 mm in size.  
 
Gene transfer in tumor bearing mice was carried out using polyplexes containing 50 µg 
pEGFPLuc per 20 g body weight at a concentration of 200 µg/mL DNA (in HBG, pH 7.4). The 
polyplexes were injected into the tail vein and animals were sacrificed 24 h after application. 
Indicated tissues were resected and homogenized in 1:5 diluted cell culture lysis reagent 
(Promega, Mannheim, Germany) using an IKA-Ultra-Turrax and subsequently centrifuged at 
4000 rpm at 4 °C for 20 minutes to separate insoluble cell components. Luciferase activity 
was determined at the luminometer (Lumat LB 9507, Berchtold, Germany) as described 
above using 20 µL of the supernatant. Two nanograms of recombinant luciferase (Promega, 
Mannheim, Germany) correspond to 107 light units. 
 
Intratumoral application of laterally stabilized HD O / DNA polyplexes was performed by 
using complexes containing 200 µg/mL pEGFPLuc. 100 µL of polyplex solution were slowly 
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injected into the tumor tissue. Luciferase gene expression was visualized using an IVIS® 
imaging system (Caliper Life Sciences GmbH, Rüsselsheim, Germany) at indicated points in 
time following the procedure: after intraperitoneal (i.p.) application of 100 µL luciferin sodium 
salt solution at a concentration of 60 mg/mL (in PBS, pH 7.4), mice were anaesthetized with 
isoflurane (2%) and luminescence due to luciferase reporter gene expression was imaged 
13 min after i.p. application of luciferin. Photons/sec (total flux) signals were used for 
evaluation. 
 
2.7.2 Blood sample analysis 
To circumvent aggregation of blood samples, syringes were pre-drawn with 100 µL heparin. 
Immediately after sacrificing the animals, blood samples were collected by puncture of vena 
cava inferior. For the determination of liver enzyme levels in serum all samples were allowed 
to clot at 37 °C for 4 h and were then centrifuged at 1000 rpm for 20 min at 4 °C. The 
supernatants were collected for analysis and stored at -80 °C until they were further 
analyzed. Enzymes were quantified by the Institut für klinische Chemie at the 
Universitätsklinikum Großhadern. Alkaline and aspartate aminotransaminases (AST, ALT) as 
well as alkaline phosphatase (AP) were measured using a kinetic UV test from Olympus 
(Olympus Life and Material Science, Hamburg, Germany). Glutamate Dehydrogenase 
(GDPH) in plasma was analyzed using a kinetic UV test from Hitado (Hitado Diagnostic 
Systems, Möhnesee Delecke, Germany). 
 
2.7.3 Histological examination 
A small piece of liver tissue of each sacrificed animal was fixed for 24 h in formalin solution 
(4% paraformaldehyde in PBS). After washing the organs for 1 h in running water, they were 
embedded in paraffin. Sections of 5 µm thickness were cut and stained with hematoxilyn and 
eosin for histopathological examination. 
2.8 Statistics 
Where indicated, one-way analysis of variance (ANOVA) was conducted using Duncan´s test 
as post-hoc method. The statistic significance is indicated by p-values. As a statistical 
software package, WinSTAT® 2003 for Excel (R. Fitch Software) was used. 
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3 Results 
3.1 Pseudodendritic oligoamines for gene delivery 
3.1.1 Pseudodendritic concept – synthesis of OEI core based conjugates 
Pseudodendrimers were synthesized in two steps (Fig. 6 and Fig. 7). In the first step 
pseudodendritic cores were generated by Michael addition of oligoethylenimine 800 Da (OEI) 
with a 20-fold molar excess of dioldiacrylate. Due to the excess of dioldiacrylate, crosslinking 
between OEIs was prevented and a branched structure with reactive acrylate end groups 
was created. The different diacrylates of ethylenglycol, butane-1.4-diol and hexane-1.6-diol 
applied as shown in Fig. 6 display increasing hydrophobicity (ED < BD < HD). 
 
Fig. 6: Pseudodendritic core synthesis. Oligoethylenimine 800 Da (OEI) was coupled with a 20-fold 
molar excess of different dioldiacrylates in anhydrous DMSO. Reaction proceeded for 24 h at 45 °C. 
For graphical reasons, only four branches are shown. 
 
In the following step, each OEI core (ED, BD and HD core) was further modified on its 
surface by adding an excess of either ethanolamine (E), spermidine (Sp), spermine (S) or 
OEI (O) as shown in Fig. 7. For further studies within the HD core conjugates also 
ethylenediamine (EDA), triethylenetetramine (TETA), pentaethyleneheximine (PEHI), 
oligoethylenimine 1200 Da (O1200) and oligoethylenimine 1800 Da (O1800) were used. 
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Fig. 7: Pseudodendritic surface modification. Various oligoamines were used as surface 
modification units. Surface modification of pseudodendrimers proceeded with a 30-fold molar excess 
of oligoamine to core OEI in anhydrous DMSO. Reaction proceeded for 24 h at 22 °C. 
 
The different amines were selected to increase the number of nitrogens per surface 
modification unit step by step. Conditions for synthesis including reaction temperature, 
reaction time as well as concentrations of educts were optimized in preliminary studies (data 
not shown). Under the chosen reaction conditions, neither gelation nor precipitation occurred. 
After purification by dialysis and lyophilization, all products were well water-soluble. Yields 
are given in Table 2. The nomenclature of pseudodendrimers is derived from the core moiety 
followed by the surface amine used. 
 
3.1.2 Structural characterization of pseudodendrimers 
The structural composition of the resulting products was analyzed using 1H NMR 
spectroscopy. The calculated molar diacrylate / OEI- and surface amine / OEI-ratios, the 
percentages of remaining esters and yields of pseudodendrimers after synthesis are listed in 
Table 2. 
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Table 2: Composition of pseudodendrimers determined by 1H NMR spectroscopy in D2O. The 
diacrylate to OEI ratio was determined by comparing the integrals of signals at δ 4.0 and δ 2.5 – 3.3  
that are attributed to the methylene protons of the ester group (COOCH2) and the ethylene protons of 
oligoethylenimine (NHCH2CH2), respectively. The surface amine to OEI ratio was calculated by the 
relation of the integrals of signals at δ 2.5 – 3.3 that are attributed to the ethylene protons of 
oligoethylenimine (NHCH2CH2) and of the signals specifying the investigated oligoamine. * = ratio of 
diacrylate to total OEI (core plus surface OEI). N.d.: not determined. The percentage of residual ester 
content after synthesis was determined by comparing the integrals of signals at δ 4.0 and δ 3.5 that 
are attributed to the methylene protons of the ester group and hydroxyl group (HOCH2), respectively. 
Yields are given as weight of product / weight of educts [w/w] percent.  
 
In general approximately 10 diacrylates were coupled per OEI (diacrylate / OEI-ratio) 
resulting in a tree-like pseudodendritic core structure. The ratio of surface amine to OEI was 
lower compared to the ratio of diacrylate to OEI for all conjugates, indicating that more than 
one pseudodendritic branch reacted per surface modification unit (surface amine / OEI-ratio). 
In fact, it seemed that two to three amine functionalities have reacted per surface amine and 
pseudodendritic core. Interestingly, also ethanolamine that contains only one amine 
functionality per molecule had a lower surface amine / OEI-ratio indicating that intra-
molecular side-reactions of the dioldiacrylate cannot be prevented during pseudodendritic 
core synthesis. The esters, which present the degradable bonds of the polymers, might 
aminolyze or hydrolyze during synthesis and purification. Therefore, the ester content of all 
conjugates was analyzed (Table 2); it was ranging around 90% of the theoretical value 
except for ED O, which contained only 71% of ester bonds after synthesis. As expected, all 
three different cores showed decreasing percentage of ester bonds as the number of 
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nitrogens per surface amine increased (HD core: 97% (E) to 87% (O), BD core: 94% (E) to 
85% (O), ED core: 90% (E) to 71% (O)). This can be explained by aminolysis catalyzed by 
an increasing amount of unprotonated amino groups during pseudodendrimer synthesis. 
 
The molecular weights of the pseudodendrimers were determined by gel permeation 
chromatography (GPC) measurements and are listed in Table 3.  
 
Table 3: Determination of molecular weights of pseudodendrimers by GPC measurements. Vp: 
elution volume at peak maximum; Mp: molecular weight at peak maximum; Mw: weight average 
molecular weight; Mn: number average molecular weight; PDI: polydispersity index; n.d.: not 
detectable. Molecular weights were measured relative to Pullulan molecular weight standards, which 
were used for preparing a standard calibration curve. 
 
In general, all pseudodendrimers had much lower molecular weights than the standard 
polyethylenimines LPEI and BPEI. With an increasing number of nitrogen per surface 
modification unit, all pseudodendrimers showed increasing molecular weights. For example, 
within HD core polymers molecular weights of 1410 Da for HD Sp, 2613 Da for HD S and 
4138 Da for HD O were found. However, shorter hydrocarbon spacers in the coupled 
dioldiacrylates resulted in higher molecular weights. 
 
For conjugate HD O degradation kinetic studies were carried out at physiological pH of 7 at 
37 °C over a period of 7 days. The extent of degradation was determined using 1H NMR 
spectroscopy. After 3 days, approximately 50% of the ester bonds were degraded and after 
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7 days almost no residual ester bonds were present, demonstrating that HD O is degradable 
under in vitro conditions (see Fig. 8). 
 
Fig. 8: Degradation kinetics of HD O. The decrease of remaining ester content was followed over 
time by 1H NMR spectroscopy at 37 °C at physiological pH in aqueous medium (n = 2). 
 
3.1.3 Physicochemical characterization of pseudodendrimers 
3.1.3.1 DNA condensing ability of pseudodendrimers 
For efficient gene delivery, the gene carrier must be able to condense DNA to form 
complexes suitable for cell entry. This formation was studied in an ethidium bromide (EtBr) 
exclusion assay measuring the reduction of relative fluorescence as a function of an 
increasing conjugate / plasmid weight / weight ratio (c/p-ratio) as shown in Fig. 9.  
 
When investigating the influence of the surface modification on DNA binding ability (Fig. 9A), 
a similar DNA-binding pattern was found for ED, BD or HD cores: the surface modification 
with ethanolamine (E) containing one nitrogen showed the lowest DNA binding ability 
followed by spermidine (Sp) and spermine (S) modification, with three and four nitrogens per 
coupled oligoamine, respectively. OEI (O) surface modification (18 nitrogens per coupled 
oligocation) resulted in best DNA compacting properties indicating that an improved complex 
formation capability was found with an increasing number of nitrogens per coupled 
oligocation (Fig. 9A). This corresponded to the finding that an increasing number of nitrogen 
per coupled oligoamine resulted in stepwise increased zeta-potentials resulting in an 
enhanced DNA condensing ability (see below and Table 4).  
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Regarding the influence of the core characteristics on DNA binding, it was found that a larger 
hydrocarbon spacer in the coupled dioldiacrylate increased DNA compacting capabilities 
(Fig. 9B). Thus, HD core conjugates exhibited the best DNA compacting abilities, followed by 
BD and ED core conjugates, resulting in a stepwise decreased capacity for complex 
formation. Notably, this effect was representative for ethanolamine (E), spermidine (Sp) and 
spermine (S) surface modifications, whereas OEI (O) as coupled oligocation showed similar 
good DNA compacting abilities upon all pseudodendritic cores indicating that the influence of 
the surface modification unit was able to mask core characteristics.  
 
3.1.3.2 Size and zeta-potential determination of polyplexes 
Mean hydrodynamic diameters (DLS) and zeta-potentials of DNA polyplexes with 
pseudodendrimers at a c/p-ratio 2 are listed in Table 4. HD core conjugates exhibited 
polyplex sizes around 160 nm, except for the ethanolamine modified HD core (531 nm). 
Although loose DNA compaction cannot be excluded, the tendency of HD E to aggregate at 
low c/p-ratio is consistent with the fact that BD E results in small polyplex sizes although it 
 
Fig. 9: DNA binding ability of pseudodendrimers demonstrated by ethidium bromide (EtBr) 
exclusion assay. A) Influence of the surface modification unit on DNA binding ability as demonstrated 
by a representative experiment with the HD core conjugates. B) Influence of the hydrocarbon spacer 
length in the pseudodendritic cores on DNA binding ability as demonstrated by a representative 
experiment with the ethanolamine (E) surface modification. All experiments were performed in HBG. 
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shows a lower DNA binding ability. BD core conjugates showed polyplex sizes around 
200 nm while ED core conjugates resulted in decreasing polyplex sizes with an increasing 
number of nitrogens per surface modification unit (ED E: 894 nm; ED O: 181 nm) correlating 
with their increasing DNA condensing ability. 
 
Table 4: Mean hydrodynamic diameters and zeta-potentials of pseudodendrimers. Complex 
sizes were determined at c/p-ratio 2 in HBG using dynamic light scattering 20 min after polyplex 
formation at a DNA concentration of 10 µg/mL. For zeta-potential measurements polyplexes were 
diluted 1:5 with HBG to a final DNA concentration of 2 µg/mL. Mean values (± SD) out of three 
independent measurements are shown. 
At a c/p-ratio of 2, all conjugates based on the three different pseudodendritic cores exhibited 
stepwise increasing zeta-potentials with an increasing number of nitrogens per coupled 
oligocation (Table 4). Hence, measured zeta-potentials of HD core conjugates were ranging 
from +2.7 mV (HD E) to +29 mV (HD O), BD core conjugates from +6.8 mV (BD E) to 
+25.1 mV (BD O) and ED core conjugates from -8.8 mV (ED E) to +24.0 mV (ED O). 
 
3.1.4 Influences of pseudodendrimers on cytotoxicity 
To investigate the influences of core characteristics and the surface modification on 
cytotoxicity, a lactate dehydrogenase (LDH) assay and an ATP assay were performed in 
parallel. This allows analogous monitoring of cell membrane damage (LDH assay) versus 
metabolic activity of cells (ATP assay) after treatment with various concentrations of 
pseudodendrimer. 
Fig. 10 shows the influence of the hydrocarbon spacer in the coupled dioldiacrylate, 
demonstrating that pseudodendritic core hydrophobicity correlates with cytotoxicity. 
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Fig. 10: Influences of pseudodendritic core characteristics of plain pseudodendrimers on 
cytotoxicity. The LDH release assay (A) monitors cell membrane damage and the ATP assay 
metabolic activity of cells (B) after treatment with pseudodendrimers as a function of the polymer 
concentration. Cytotoxicity increases with an increasing aliphatic spacer in the coupled dioldiacrylate, 
i.e. increasing core hydrophobicity enhances toxic effects. All experiments were performed in Neuro2a 
cells in triplicates. 
 
 
In the particular example shown in the figure, ethanolamine was applied as representative 
surface amine. While BD and ED cores did not show any LDH release from the cytoplasm of 
treated cells, the HD core bearing a C6 spacer exhibited membrane damage in a dose 
dependent manner (Fig. 10A). In parallel, metabolic activity of treated cells decreased with 
the length of the C-spacer, shown by the rapid decrease of cell viability after HD E treatment 
(Fig. 10B). BD E and ED E exhibited rather low or no decrease of metabolic activity in cells 
after conjugate treatment also not at the highest tested concentration of 1 mg/mL. 
 
Investigating the influence of the surface modification on cytotoxicity, it was found that with a 
rising number of nitrogens per coupled oligoamine a stepwise increased cytotoxic effect was 
detectable. This can be seen best in the ED core series (Fig. 11). 
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Fig. 11: Influences of pseudodendritic surface modification of plain pseudodendrimers on 
cytotoxicity. The LDH release assay (solid lines) monitors cell membrane damage and the ATP 
assay the metabolic activity of cells (dashed lines) after treatment with pseudodendrimers. Cytotoxicity 
increases with an increasing number of nitrogen per surface modification unit. All experiments were 
performed in Neuro2a cells in triplicates.   
 
Hence, the ethanolamine conjugate bearing one nitrogen per surface modification unit 
(E = 1N) showed neither a decrease of metabolic activity nor an increase of LDH release 
whereas the spermidine surface modification (Sp = 3N) with a concentration above 
0.5 mg/mL resulted in decreased cell viability while no membrane damage was detectable. A 
higher number of nitrogens upon the surface obviously boosted cytotoxic effects consisting of 
membrane damage and decreased metabolic activity of cells after pseudodendrimer 
treatment as shown by spermine (S = 4N) and OEI (O =  18N) surface modifications. 
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3.1.5 Gene transfer activity: structure-activity relationship in vitro 
Reporter gene expression (luciferase activity) and parallel cytotoxicity (MTT assay) studies of 
all pseudodendrimers were evaluated in B16F10, murine melanoma and Neuro2a, murine 
neuroblastoma cells in order to determine a structure-activity relationship in vitro. The 
plasmid pCMVLuc encoding for firefly luciferase was used as reporter gene at a DNA 
concentration of 20 µg/mL. Polyplexes were prepared in HBG and cells were incubated in the 
presence of 10% fetal calf serum for 4 h. For LPEI and BPEI, used as references in all 
experiments, a c/p-ratio of 0.8 (i.e. nitrogen/phosphate N/P-ratio of 6) was used. This was 
optimized in preliminary studies in both cell lines (data not shown).18 
 
In first screening studies the best c/p-ratios (weight ratios of conjugate to pDNA) for HD core, 
BD core and ED core pseudodendrimers were determined in both, B16F10 and Neuro2a 
cells (see Fig. 12, Fig. 13 and Fig. 14). 
 
For most of the conjugates optimized transfection conditions, i.e. highest reporter gene 
expression at lowest cytotoxicity levels (> 75% metabolic activity of cells 24 h post 
transfection), were found at a c/p-ratio of 2. 
 
Fig. 12: Optimized c/p-ratio finding of HD core conjugates. In Neuro2a cells (A) and B16F10 cells 
(B) in the presence of 10% serum. All polyplexes were prepared at indicated c/p-ratios in HBG. LPEI 
and BPEI were applied at optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Data is 
expressed as mean values (± SD) out of three independent experiments each performed in 
triplicates. RLU / number of cells represents the measured relative light units referred to the number 
of cells at the time point of cell plating. 
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Fig. 13: Optimized c/p-ratio finding of BD core conjugates. In Neuro2a cells (A) and B16F10 cells 
(B) in the presence of 10% serum. All polyplexes were prepared at indicated c/p-ratios in HBG. LPEI 
and BPEI were applied at optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Data expressed 
as mean values (± SD) out of three independent experiments each performed in triplicates. 
RLU / number of cells represents the measured relative light units referred to the number of cells at 
the time point of cell plating. 
 
Fig. 14: Optimized c/p-ratio finding of ED core conjugates. In Neuro2a cells (A) and B16F10 cells 
(B) in the presence of 10% serum. All polyplexes were prepared at indicated c/p-ratios in HBG. LPEI 
and BPEI were applied at optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Data expressed 
as mean values (± SD) out of three independent experiments each performed in triplicates. 
RLU / number of cells represents the measured relative light units referred to the number of cells at 
the time point of cell plating. 
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To investigate both the effects of the different pseudodendritic core characteristics and the 
impacts of the various surface modifications on transfection efficiency and cytotoxicity all 
compounds were studied in parallel. For direct comparison Fig. 15 shows the influences in 
both Neuro2a and B16F10 cells. 
 
 
Fig. 15: Influence of the hydrocarbon spacer in dioldiacrylates and the influence of the surface 
modification unit in pseudodendrimers on transfection efficiency (left, luciferase assay) and 
metabolic activity (right, MTT assay). In Neuro2a cells (A) and B16F10 cells (B) in the presence of 
10% serum. All polyplexes were prepared at c/p-ratio of 2 in HBG. LPEI and BPEI were applied at 
optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Data expressed as mean values (± SD) 
out of three independent experiments each performed in triplicates. RLU / number of cells represents 
the measured relative light units referred to the number of cells at the time point of cell plating.  
(ANOVA, Duncan’s test, * p < 0.05, *** p < 0.001 ED vs. HD, ♦ p < 0.05, ♦♦♦ p < 0.001 BD vs. HD) 
 
Regarding the effects of the pseudodendritic core characteristics on reporter gene 
expression levels, significantly enhanced transfection efficiency was detected for the HD core 
polymers over their BD and ED core counterparts. The improved transfection levels from ED 
to BD core conjugates were not significant. Only one exception was found for ED O that 
showed highest reporter gene expression levels in B16F10 cells, which was a cell-type 
specific effect (Fig. 15B, left). According to the influences of the surface modification on 
transfection efficiency it was found that within the HD and the ED core conjugates a step by 
step rise of the transfection level occurred by increasing the number of nitrogens per coupled 
oligocation (E < Sp < S < O). This effect was almost independent of all investigated c/p-
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ratios. BD core conjugates, however, did not show such a direct correlation and mediated 
moderate transfection in both cell lines. 
Furthermore, in cytotoxicity studies with BD and ED core conjugates no significant cytotoxic 
differences for all surface modifications (Fig. 15, right) were detected. Nevertheless, 
increasing the core hydrophobicity decreased metabolic activity at the same time i.e. 
increased cytotoxicity. Thus, after HD E, HD Sp and HD S polyplex treatment metabolic 
activity of cells significantly decreased as compared to their ED and BD core counterparts. 
Interestingly however, the best transfection conjugate HD O complexed with DNA did not 
exhibit such a decreased metabolic activity and cell viability was maintained high.  
 
 
Fig. 16: In vitro transfection efficiency (left, Luciferase assay) and metabolic activity (right, MTT 
assay) of HD core pseudodendrimers. Transfection was carried out in Neuro2a cells (A) and in 
B16F10 cells (B) in the presence of 10% serum. Polyplexes were formed at indicated c/p-ratios in 
HBG; luciferase activity and metabolic activity were determined 24 h post transfection. LPEI (22 kDa) 
and BPEI (25 kDa) were applied at optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Data 
expressed as mean values (± SD) out of three independent measurements each performed in 
triplicates. RLU / number of cells represents the measured relative light units referred to the number of 
cells at the time point of cell plating. Surface modifications upon the HD core: ethanolamine (E), 
ethylenediamine (EDA), spermidine (Sp), spermine (S), triethylenetetramine (TETA), 
pentaethyleneheximine (PEHI), OEI 800 Da (O), OEI 1200 Da (O1200), OEI 1800 Da (O1800). 
 
To investigate this effect in more detail, additional five surface modification units within the 
HD core line were studied. These modification units were ethylenediamine (EDA), 
triethylenetetramine (TETA), pentaethyleneheximine (PEHI), oligoethylenimine 1200 Da 
(O1200) and oligoethylenimine 1800 Da (O1800) (see Fig. 7). 
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Fig. 16 demonstrates that high transfection levels at low cytotoxicity apparently depend on 
an optimized balance of core characteristics and the surface amine used. This is only the fact 
in case of HD O, exhibiting highest transfection levels at low toxicity in both Neuro2a and 
B16F10 cells. 
 
Importantly, HD O showed in both cell lines similar high reporter gene expression levels as 
the standard polyethylenimines LPEI and BPEI. Especially in Neuro2a cells HD O exhibited 
similar high transfection levels as LPEI and was about 100-fold more efficient than BPEI (all 
at their optimized c/p-ratios). Since polymers may differently affect the protein levels of 
transfected cells due to differential toxicity and cell proliferation transfection levels were 
quantified side-by-side as RLU / mg of protein and RLU / number of seeded cells in separate 
experiments analogous to Fig. 15 and Fig. 16. The gene expression pattern of the different 
polymers in the two normalizations was almost identical, thus, ruling out significant effects on 
protein levels (data not shown).  
 
Fig. 17 shows the comparison of the best transfecting conjugate HD O versus LPEI and 
BPEI polyplexes at EGFP expression levels in Neuro2a cells.  
 
Fig. 17: EGFP expression studies of LPEI, BPEI and HD O in Neuro2a cells. All polyplexes were 
applied at their optimized c/p-ratios (in HBS) as indicated in the pictures. 24 h after transfection, cells 
were examined with a Zeiss Axiovert 200 microscope and above shown pictures were taken using an 
Axiocam camera using appropriate filters for EGFP excitation and emission. Further analysis of 
unfixed cells was performed using FACS analysis. The percentage of EGFP positive cells is indicated 
at brackets in the pictures. MFI represents mean fluorescence intensities of cells.  
 
Mean fluorescence intensities (MFI) mediated by HD O and LPEI polyplexes were high, 
whereas BPEI in contrast showed a much lower fluorescence signal. LPEI and HD O also 
showed high percentage of EGFP positive cells (69% and 24%, respectively, as determined 
by flow cytometry), while BPEI polyplexes only transfected 1% of cells. 
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3.2 In vivo studies of promising OEI core based conjugates 
Under in vitro conditions both compounds, HD S and HD O, resulted in high transfection 
efficiency levels at rather low cytotoxicity. Thus, they were further investigated in detail with 
regard to a potential in vivo application.  
 
3.2.1 Biocompatibility studies of HD S and HD O in vitro and in vivo 
After systemic application of positively charged polyplexes it is likely that undesired side 
effects of unbound polymer within the applied polyplexes may lead to interactions with 
several blood components including erythrocytes.15 This may result in hemolysis and / or 
aggregated blood components e.g. due to membrane destabilizing effects of the polymers. 
Aggregated erythrocytes finally may cause an entrapment in small capillaries like e.g. in the 
lung resulting in acute toxic effects. 
 
Thus, prior to in vivo application of polyplexes in mice, both the hemolytic activity of 
pseudodendrimers as well as their tendency to induce erythrocyte aggregation was studied 
using freshly isolated human erythrocytes. 
Erythrocytes were incubated with different concentrations of plain polymers ranging from 
50 µg/mL to 200 µg/mL at physiological pH of 7.4 for 45 min at 37 °C. The released 
hemoglobin concentration was determined by optical absorbance at 405 nm representing 
λmax of hemoglobin. HD S and HD O exhibited distinct membrane destabilizing activity (up to 
90% relative to Triton-X  representing 100% hemolysis) if plain polymer was used. 
Importantly, no polymer induced erythrocyte aggregation was found under these conditions 
(data not shown). In order to adjust experimental conditions to the in vivo situation, hemolytic 
activity of plain HD S and HD O was studied in the presence of 10% serum. Already at this 
low concentration of serum, in both cases hemolytic activity was strongly reduced by the 
presence of serum proteins. For instance, at a concentration of 50 µg/mL, HD O induced 
80% erythrocyte lysis in the absence, but only 37% lysis in the presence of serum. Again, no 
polymer induced erythrocyte aggregation was found under these conditions (data not 
shown). 
 
Standard high molecular weight polycations used for in vivo application, such as LPEI or 
BPEI, are known to induce strong erythrocyte aggregation, even in the presence of serum, 
while their hemolytic activity is rather low (see also Fig. 26). 
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First studies on acute toxicity in mice revealed that at a concentration of 50 µg/mL HD S as 
plain conjugate was highly toxic after i.v. application resulting in lethality of mice, whereas 
HD O was well tolerated. The same results were found in preliminary studies using 
polyplexes. 
 
3.2.2 Gene transfer studies of HD O polyplexes in vivo 
As HD O was well tolerated by mice, it was further investigated for its in vivo gene transfer 
ability in tumor bearing mice. The experiments were conducted by intravenous injection of 
complexes of HD O (c/p-ratio 1 and 2) as well as LPEI and BPEI as references (c/p-ratio 0.8 
= N/P-ratio 6) using pEGFPLuc as reporter gene. Complexes were prepared at a final DNA 
concentration of 200 µg/mL in HBG with 50 µg DNA applied per 20 g mouse. Mice receiving 
polyplexes showed no signs of acute toxicity. Fig. 18 presents luciferase reporter gene 
expression in main organs and tumor tissue 24 h after intravenous application of polyplexes.  
 
Fig. 18: Luciferase gene expression 24 h after i.v. administration of polyplexes into mice 
bearing s.c. Neuro2a tumors. HD O was applied at c/p-ratios of 1 and 2, LPEI and BPEI at c/p-ratio 
0.8 (representing an N/P-ratio of 6). Luciferase gene expression is presented as relative light units per 
organ or tumor (RLU / organ) (mean ± SD, n = 3 animals per group). Tumor weights ranged between 
250 and 300 mg. Two nanograms of recombinant luciferase correspond to 107 light units.  
(ANOVA, Duncan’s test, *** p < 0.001 and ** p < 0.01 for LPEI vs. HD O and BPEI) 
 
Consistent with previous work, the application of LPEI polyplexes led to luciferase gene 
expression in all investigated organs but was predominantly found in the lung (>100-fold 
higher compared to all other organs and tumor tissue). BPEI exhibited reporter gene 
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expression mainly in tumor tissue, liver and lung at lower levels compared to LPEI. At both 
c/p-ratios the pseudodendrimer HD O resulted in transgene expression that was found 
predominantly in tumor tissue at gene expression levels comparable to LPEI. Importantly, for 
HD O at a c/p-ratio of 1 far lower luciferase gene expression was observed in the lung 
(tumor / lung ratio (T/L) ~20) and no significant transgene expression was observed in any 
other organ.  
 
3.2.3 Biocompatibility of HD O polyplexes in vivo 
A 6% loss of body weight was observed 24 h after injection of HD O polyplexes at c/p-ratio 1 
whereas at c/p-ratio 2 a loss of body weight of 14% was found, showing no significant 
differences compared to LPEI (11%) and BPEI (14%) in both cases. 
The biocompatibility of HD O (c/p-ratio 1) was further assayed in tumor-free mice. No 
increase of liver enzyme levels (AST, ALT, GLDH and AP) was found as compared to a 
buffer (HBG) treated control. In contrast, LPEI and BPEI (both at a c/p-ratio of 0.8) showed 
increased liver enzyme levels (for BPEI being statistically significant, * p < 0.05, ANOVA, 
Duncan’s test), indicating the beginning of necrotic changes (Fig. 19 and Fig. 20). 
 
 (AST + ALT)/GLDH AP 
HBG 4.9 (± 1.4) 225 (± 37) 
HD O c/p 1 6.3 (± 2.6) 190 (± 47) 
LPEI c/p 0.8 11.7 (± 4.7) 189 (± 15) 
BPEI c/p 0.8 17.3 (± 8.6) * 253 (±  9) 
Fig. 19: Liver enzyme levels in serum 24 h after polyplex treatment. Alkaline (ALT) and aspartate 
(AST) aminotransaminases, glutamate dehydrogenase (GLDH) and alkaline phosphatase (AP). Data 
represents mean values (± SD, n = 3 animals per group), except buffer (n = 4).  
 
 
Histopathologic examinations underline these findings as shown in Fig. 20, where no 
changes in liver histology were found in case of HD O compared to the buffer treated control. 
In contrast, LPEI led to necrotic changes in liver tissue as indicated by the arrows and BPEI 
resulted in microvesicular fatty liver already after 24 h shown by inclusion of lipid droplets 
within the hepatocytes. 
3 Results  45 
 
 
Fig. 20: Histologic examinations (H/E staining) on liver tissue. 24 h after polyplex treatment, HD O 
c/p-ratio 1 showed no changes in liver histology compared to HBG treated control. Necrotic areas in 
the liver are indicated by the arrows after LPEI treatment. Lipid droplets in hepatocytes in case of 
BPEI treated mice show a microvesicular fatty liver (arrows). (Upper left, control (HBG); upper right, 
HD O c/p-ratio 1; lower left, LPEI c/p-ratio 0.8; lower right, BPEI c/p-ratio 0.8).  
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3.3 Grafted PPI dendrimers: modification of G2 and G3 core 
derivatives 
In order to obtain a better defined core unit than the randomly branched OEI, the studies 
were extended toward polypropylenimine (PPI) dendrimers as core moiety. To compare 
influences of different dendrimer generations within the core unit on physicochemical and 
biological properties, generation 2 (G2) and generation 3 (G3) PPI dendrimers were grafted. 
As grafting moieties either OEI or PPI dendrimer G2 was used in order to define differences 
between ethylenimine and propylenimine moieties upon the pseudodendritic surface. 
 
Fig. 21: Synthesis scheme of grafted polypropylenimine dendrimers. G2-HD-OEI, G2-HD-G2, 
G3-HD-OEI and G3-HD-G2 synthesis proceeded similarly and is exemplified here for the generation 2 
(G2) core derivative G2-HD-OEI. For graphical reasons, only four (instead of eight) branches are 
shown. 
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3.3.1 Synthesis and characterization of grafted dendrimers 
Grafted PPI dendrimers were synthesized in analogous fashion as described for OEI core 
based pseudodendrimers via Michael addition of PPI G2 or PPI G3 using hexane – 1.6 – 
dioldiacrylate (HD) as biodegradable linker (Fig. 21). 
 
The HD linker was used since it was found in preliminary studies using PPI G2 dendrimers 
modified with a series of different bisacrylates that HD revealed the highest transfection 
levels (data not shown) which is also in accordance to the results described above. To 
prevent crosslinking between core units, a 20-fold (G2 HD core) or 45-fold (G3 HD core) 
molar excess of dioldiacrylate was used during core synthesis and a branched structure with 
acrylate reactive end groups was formed. In the following step, these core units (G2 HD or 
G3 HD) were grafted by adding an excess of either OEI or G2 as shown in Fig. 21, resulting 
in G2-HD-OEI, G2-HD-G2, G3-HD-OEI or G3-HD-G2. All products were well water-soluble 
and yields of obtained compounds were listed in Table 5.  
 
Table 5: Structural composition of grafted PPI dendrimers determined by 1H NMR spectroscopy 
(D2O). The HD to core ratio (HD / core) was determined by comparing the integrals of signals that are 
attributed to the methylene protons of the ester group (COOCH2) and the ethylene protons of 
polypropylenimine, respectively. The grafting unit to PPI core ratio (GU / core) was calculated by the 
relation of the integrals which are attributed to the protons of propylenimine and of the signals 
specifying OEI. N.d.: not determined. The percentage of residual ester content after synthesis was 
determined by comparing the integrals of signals at δ 4.0 and δ 3.5 that are attributed to the 
methylene protons of the ester group and hydroxyl group (HOCH2), respectively. Yields are given as 
weight of product / weight of educts [w/w] percent. Molecular weights were determined by GPC. Mw: 
weight average molecular weight; Mn: number average molecular weight; PDI: polydispersity index. t1/2 
was determined after certain intervals by comparing the integrals of signals at δ 4.0 and δ 3.5 that are 
attributed to the methylene protons of the ester group (COOCH2) and hydroxyl group (HOCH2), 
respectively. 
 
The PPI derivatives were analyzed by 1H NMR spectroscopy to determine their structural 
composition (see Table 5). The molar ratio of HD coupled per core unit (G2 or G3) was 
calculated by comparing NMR peak intensities between the protons of HD (δ 4.0 ppm) and 
PPI (δ 1.7 – 2 ppm). For the G2 core, 8 HD per core unit have coupled whereas for the G3 
core unit 16 HD molecules have bound. This indicated that no intramolecular side reactions 
have occurred. The molar ratio of grafting unit (GU) / core was determined by comparing the 
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integrals of OEI protons (δ 2.4 – 3.4 ppm) with the core unit PPI protons. The molar ratio of 
grafting G2 and G3 core units with G2 cannot be determined by 1H NMR spectroscopy. 
Generally, the GU / core ratio was lower than the HD / core ratio indicating that more than 
one dendritic branch per grafting unit might have reacted. Since the esters, which present the 
degradable bonds of the polymers, might aminolyze or hydrolyze during synthesis and 
purification, the ester content of all conjugates was analyzed. It ranged around 80% of the 
theoretical value (Table 5). 
 
GPC measurements for the determination of molecular weights of the grafted dendrimers 
showed that G3 core dendrimers resulted in higher molecular weights than G2 core 
derivatives as depicted in Table 5. However, both conjugates that were grafted by G2 
resulted in much higher molecular weights than the OEI grafted ones, which can be 
explained by an insufficient solubility of these polymers in the mobile phase. PDIs were 
ranging from 1.2 to 2.5 indicating a low- to mid-ranged polydispersity of the products. 
 
Ester degradation of all PPI derivatives was followed by 1H NMR spectroscopy at pH 7 at 
37 °C in aqueous medium. The extent of degradation was determined by comparing the 
integrals of signals at δ 4.0 ppm and δ 3.5 ppm that are attributed to the methylene protons 
of the ester group (COOCH2) and hydroxyl group (HOCH2), respectively. Table 5 gives t1/2 for 
all grafted dendrimers. It is obvious that the OEI grafted derivatives, G2-HD-OEI and 
G3-HD-OEI, were degraded much faster under physiological conditions (t1/2 = 3 days) than 
the G2 grafted ones, G2-HD-G2 and G3-HD-G2 (t1/2 > 14 days). It is likely that their lower 
water solubility due to the more hydrophobic propylenimine moieties upon the surface 
reduced ester hydrolysis, thus increasing their t1/2.  
 
3.3.2 Physicochemical characterization of grafted PPI dendrimers 
3.3.2.1 DNA condensing ability 
The capability of grafted G2 and G3 core dendrimers to complex DNA was investigated using 
an ethidium bromide exclusion assay as a function of increasing c/p-ratios [w/w] (Fig. 22). All 
grafted dendrimers showed a very good DNA condensing ability already at low c/p-ratios if 
HBG (low ionic strength buffer) was used for complex formation. This was indicated by the 
very low c/p-ratios needed to obtain Fl50% that was found for all derivatives at c/p-ratio 0.4 
(see Fig. 22A). Interestingly, unmodified dendrimer G3 exhibited in HBG the lowest c/p-ratio 
to reach Fl50% (c/p = 0.2) whereas the unmodified G2 dendrimer showed the highest value 
(c/p for Fl50% = 0.8), indicating its weaker capability to condense DNA. All constructs 
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displayed low minimum values of relative fluorescence in HBG showing a high binding 
strength in a low ionic strength buffer. Nevertheless, it can be clearly seen that in presence of 
sodium chloride (HEPES buffered saline, 0.15 M NaCl = HBS, Fig. 22B) the DNA binding 
strength within the complexes was dramatically decreased, since the obtained minimum 
relative fluorescence increased for all conjugates from about 3 – 10% (in HBG) to 20 – 30% 
(in HBS). This effect was found for either the unmodified as well as for the grafted 
dendrimers, notably, irrespective of the dendrimer generation within the core unit or the 
investigated grafting moiety used. Similar effects were also found for standard 
polyethylenimines like LPEI (22 kDa) or BPEI (25 kDa) and other polycationic gene delivery 
vectors.37 
 
Fig. 22: DNA condensation ability of grafted PPI dendrimers studied by ethidium bromide 
(EtBr) exclusion assay. Experiments were carried out in HEPES buffer glucose 5% (HBG; low ionic 
strength condition) (A) and in HEPES buffer saline 0.15 M NaCl (HBS; physiological ionic strength 
condition) (B). C/p for Fl50% represents the c/p-ratio to quench to 50% fluorescence of the original 
value. Flmin indicates minimal fluorescence and represents the binding strength. 
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3.3.2.2 Stability of polyplexes against NaCl induced disassembly 
To clarify in which extent the stability of unmodified or grafted PPI core based polyplexes 
was affected by salt, their colloidal stability was studied. For this the dissociation to free DNA 
and free polycation was investigated as a function of an increasing amount of sodium 
chloride via light scattering. Light scattering is a convenient procedure to measure complex 
formation or complex dissociation since the intensity of scattered light is dramatically 
increased when complexes are formed, especially if they aggregate, compared to free DNA 
and polycation where scattering intensity is low.66 Fig. 23 shows the intensity of scattered 
light of grafted and unmodified polyplexes (c/p-ratio 2) as a function of the sodium chloride 
concentration. It can be assumed that all polyplexes aggregated at 0.25 M NaCl since 
scattered light intensity was at maximum. 
 
 
Fig. 23: Stability of polyplexes against dissociation with sodium chloride (NaCl). The colloidal 
stability of polyplexes against NaCl was evaluated using light scattering (λex = λem = 600 nm). Stepwise 
addition of 5 M NaCl to the polyplex solution resulted in the decrease of scattering intensity as a 
function of an increasing molar NaCl concentration. 
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A rapidly decreasing scattering intensity was observed for unmodified G2 polyplexes 
immediately after salt addition at sodium chloride concentrations higher than 0.25 M and the 
lowest intensity occurred at 0.75 M NaCl resembling total polyplex disassembly at this point. 
The higher generation dendrimer G3 (unmodified) started to dissociate at 0.5 M NaCl and the 
minimum of scattering intensity was found at 1 M sodium chloride. With regard to the grafted 
dendrimers it was found that the complexes were not as susceptible to NaCl induced 
dissociation as compared to their unmodified counterparts. This was either demonstrated by 
the shift of the point of disassembly to higher salt concentrations and/or the minimum of 
scattering intensity. For example, the G2-HD-OEI complex started to dissociate at 0.5 M 
NaCl with a scattering minimum at 1 M NaCl whereas for the G3-HD-OEI polyplex a 
scattering minimum at 1.5 M NaCl was detected. This indicates the increased colloidal 
stability of the G3 core over the G2 core. Interestingly, all the derivatives that were G2 
grafted were less sensitive to sodium chloride compared to the OEI grafted ones; most 
probably due to the higher hydrophobicity of these polyplexes resulting in lower water 
solubility thus minimizing the possibility of salt molecules to interfere with the electrostatic 
interactions between DNA and polycation.  
 
3.3.2.3 Hydrodynamic diameter and zeta-potential of polyplexes 
Hydrodynamic diameters and zeta-potentials of all compounds were examined in HBG and 
HBS at c/p-ratios ranging from 1 to 8 (Table 6). 
 
Table 6: Hydrodynamic diameters of grafted PPI dendrimer polyplexes. C/p–ratios ranging from 
1 to 8 were investigated in HBG (5% glucose; low ionic strength condition) or HBS (0.15 M NaCl; 
physiological ionic strength condition). Data expressed as mean values (± SD) out of three 
independent experiments. 
 
If HBG was used as solvent, all conjugates resulted in mean diameters between 100 nm and 
200 nm, except for unmodified dendrimer G2 (250 – 300 nm). Unmodified G3 compared to 
unmodified G2 dendrimer resulted in smaller complex sizes at all c/p-ratios. Compared to 
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their unmodified counterpart, both OEI and G2 grafted G2 core derivatives showed smaller 
polyplex sizes at all c/p-ratios. Interestingly, grafted G3 core dendrimers resulted in a slight 
increase of complex size that was not significant. Differences between polymers having 
either OEI or G2 as grafting unit were not found. In HBS (0.15 M NaCl), complex sizes of 
grafted dendrimers increased to mean diameters ranging from 200 nm to 650 nm while 
unmodified G2 and G3 dendrimers aggregated under these conditions. The polydispersity 
indices of all samples shown in Table 6 ranged mostly between 0.2 and 0.3, indicating a low 
or mid-ranged polydispersity of polyplexes.  
 
Regarding the surface charge, it was found that increasing the c/p-ratios resulted in rising 
zeta-potentials (data not shown). In general, all compounds had zeta-potentials ranging from 
around +25 mV (c/p-ratio 1) to +30 mV (c/p-ratio 8). Importantly, the more hydrophobic 
compounds G2-HD-G2 and G3-HD-G2 resulted in slightly higher zeta-potentials than the OEI 
grafted ones. 
 
3.3.3 Gene transfer activity of grafted PPI dendrimers in vitro: the 
necessity of OEI 
3.3.3.1 Reporter gene expression and cytotoxicity in vitro 
In vitro transfection of grafted dendrimers was carried out as described above in both 
B16F10 cells (murine melanoma) and Neuro2a cells (murine neuroblastoma). LPEI (22 kDa) 
and BPEI (25 kDa) polyplexes were used as positive controls at their optimized c/p-ratio of 
0.8. Complexes were prepared in HBG.  
 
Fig. 24 shows the transfection efficiency and cytotoxicity profile of all conjugates at a c/p-
ratio range of 1 to 8. The transfection results in both cell lines demonstrated that according to 
the unmodified dendrimers, G2 polyplexes were less efficient than G3 ones – even though 
polyplexes of G2 were less toxic than those of G3, which is in accordance to previous 
findings by Zinselmeyer et al..69 
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Fig. 24: Influence of grafting upon PPI dendrimers G2 and G3 and the influence of the 
investigated grafting moiety on transfection efficiency and metabolic activity as demonstrated 
in B16F10 cells (A) and Neuro2a cells (B). Transfection studies were performed in the presence of 
10% serum and reporter gene expressions as well as metabolic activity of cells were evaluated 24 h 
post transfection. Polyplexes were formed at indicated c/p-ratios in HBG; LPEI and BPEI were applied 
at optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Transfection efficiency is expressed as 
RLU / well and is the mean (± SD) out of three independent measurements each performed in 
triplicates. Two nanograms of recombinant luciferase correspond to 107 light units.  
(ANOVA, Duncan’s test, * p < 0.05, ** p < 0.01 unmodified dendrimers vs. OEI grafted ones; ♦ p < 0.05 
G2 grafted vs. OEI grafted dendrimer; ◊ p < 0.05 BPEI vs. OEI grafted dendrimer) 
 
Grafting of either G2 or G3 core units with OEI led to enhanced transfection efficiency, 
irrespective of the investigated core generation used. Thus, comparing the OEI grafted G2 
core conjugate with its unmodified counterpart, more than 200-fold increased transfection 
efficiency from G2 to G2-HD-OEI (p < 0.01) can be detected in both tested cell lines - 
B16F10 and Neuro2a cells (Fig. 24). In this case, cell-type specific differences were found 
regarding the optimized conditions leading to highest transfection efficiency (B16F10 cells: 
c/p-ratio of 4; Neuro2a cells: c/p-ratio of 2 at metabolic activity > 80% relative to untreated 
cells). For G2-HD-G2, a very inconvenient toxicity profile dramatically reduced the polyplex 
transfection levels. 
 
The best transfecting conjugate within the G3 line, G3-HD-OEI, resulted in enhanced 
transfection efficiency as compared to both the unmodified counterpart G3 as well as 
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G3-HD-G2. Thus, e.g. in B16F10 cells the improvement from the unmodified G3 to 
G3-HD-OEI was about 30-fold (p < 0.05) while comparing G3-HD-OEI and G3-HD-G2, both 
exhibiting a similar metabolic activity of around 85% post transfection, G3-HD-OEI was 9-fold 
(p < 0.05) more efficient than G3-HD-G2. Concerning the comparison of G2 and G3 core 
derivatives due to influences of the dendrimers´ generation on transfection efficiency, it has 
to be assessed that the higher generation within the core unit of the derivatives did not 
enhance transfection efficiency in vitro. However, differences according to the improved 
cytotoxicity profile of G3 core based derivatives were found as compared to G2 core ones 
causing an improved transfection/toxicity relation (G2-HD-G2 ↔ G3-HD-G2).  
 
3.3.3.2 Bafilomycin A1 experiments 
The higher potency of OEI grafted dendrimers over G2 grafted derivatives may be explained 
by enhanced endosomolytic activity based on the proton-sponge effect13,70 of the 
oligoethylenimine moiety. To investigate this in more detail, luciferase gene transfer 
experiments were conducted in absence or presence of bafilomycin A1 in either B16F10 
(Fig. 25A) and Neuro2a cells (Fig. 25B). Bafilomycin A1 specifically inhibits the vacuolar 
type of H+ - ATPases by inhibiting the endo-/lysosomal proton pump being responsible for the 
reported decrease of polyethylenimine-mediated transfection.71 Fig. 25 illustrates the 
differences in observed luciferase expression levels. In these studies, all complexes were 
applied at their optimized c/p-ratios depending on the cell line investigated. LPEI and BPEI 
(tested as positive controls) showed a 20-fold decrease of transfection efficiency in presence 
of bafilomycin A1 in B16F10 cells (p < 0.01) and a 5- (LPEI) to 7-fold (BPEI) decrease in 
Neuro2a cells (p < 0.05), respectively. Similar cell-type specific effects after bafilomycin A1 
treatment were previously described by Kichler et al..71 Unmodified PPI dendrimers G2 and 
G3 showed no drop of luciferase expression in presence of bafilomycin A1 in both cell lines. 
The same result was detected for the PPI dendrimers grafted with G2. Only G3-HD-G2 in 
B16F10 cells displayed a minor reduction (p < 0.05) of luciferase expression in presence of 
bafilomycin A1.  
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Fig. 25: Effect of bafilomycin A1 on transfection efficiency. B16F10 cells (A) or Neuro2a cells (B) 
were transfected with unmodified (G2 or G3) dendrimers or grafted ones (G2-HD-OEI, G2-HD-G2, 
G3-HD-OEI or G3-HD-G2) in absence or in presence of bafilomycin A1. LPEI and BPEI polyplexes at 
their optimized N/P-ratio of 6 (c/p-ratio 0.8) were included for comparison. Polyplexes were applied at 
c/p-ratio of 2, except for unmodified and grafted G2 dendrimers in B16F10 (c/p-ratio 4). Data 
expressed as mean values (± SD) out of three independent experiments, each performed in triplicates. 
Two nanograms of recombinant luciferase correspond to 107 light units.  
(ANOVA, Duncan’s test, *p < 0.05, **p < 0.01, ***p < 0.001 absence vs. presence of bafilomycin A1) 
 
In sharp contrast, polyplexes with OEI grafted dendrimers G2-HD-OEI and G3-HD-OEI 
experienced a very significant (p < 0.001) 20- to 40-fold drop of luciferase activity in presence 
of bafilomycin A1 in B16F10 cells – very similar to LPEI or BPEI (Fig. 25A). In Neuro2a cells 
(Fig. 25B) this bafilomycin effect was not as pronounced, with a 5-fold (p < 0.01) reduction 
for G2-HD-OEI and 16-fold (p < 0.001) for G3-HD-OEI, again very similar as for PEI. No 
detectable cytotoxic effects of bafilomycin A1 (by measuring protein content in cell lysates 
using the BCA assay) were found, thereby ruling out that the decrease of luciferase 
expression is based on bafilomycin A1 induced toxicity (data not shown). 
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3.3.4 Biocompatibility and gene transfer studies in vivo 
Both the hemolytic activity of grafted and unmodified dendrimers as well as their tendency to 
induce erythrocyte aggregation was studied using freshly isolated erythrocytes using the 
same procedure as for OEI core based pseudodendrimers. Erythrocytes were incubated with 
different concentrations of plain polymer ranging from 5 µg/mL to 50 µg/mL (Fig. 26). 
 
 
Fig. 26: Hemolytic activity of plain grafted PPI pseudodendrimers. Freshly collected human 
erythrocytes were incubated with increasing concentrations of polymer and hemolysis was determined 
by UV measurement (λ = 405 nm) relative to Triton X (100% lysis) and a buffer treated control 
(HBG / 10% FCS). Data expressed as means out of triplicate (± SD). 
 
For unmodified dendrimers a very low hemolytic activity was found (around 2%). Similar 
results were obtained for BPEI (25 kDa) whereas LPEI (22 kDa) resulted in a dose-
dependent increase of hemolytic activity from 2% to 17%. All grafted dendrimers showed an 
increased hemolytic activity as compared to their unmodified counterparts. Interestingly, 
similar toxicity profiles as found in transfection studies were also discovered here. Thus, the 
more hydrophobic G3 core derivatives resulted in a lower hemolytic activity ranging between 
2% and 7%, whereas G2 core derivatives exhibited a higher lytic activity (7 – 12%). The 
higher toxicity of G2-HD-G2 over G2-HD-OEI was also detected here since the highest 
concentration tested (50 µg/mL) resulted in hemolysis ranging around 20% whereas 
G2-HD-OEI showed a lytic activity of only up to 10%. 
 
Investigations regarding polymer induced erythrocyte aggregation showed that unmodified 
and all grafted dendrimers did not lead to polymer-induced erythrocyte aggregation 
(see Fig. 27). In contrast, standard PEIs – as already known – caused strong erythrocyte 
aggregation.15,37  
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Fig. 27: Polymer induced erythrocyte aggregation. Erythrocyte aggregation after polymer 
treatment was determined by transmitted light microscopy (20-fold magnification). Pictures represent 
erythrocyte aggregation at a concentration of polymers c = 50 µg/mL. 
 
G2-HD-OEI and G3-HD-OEI, found as best transfecting compounds in in vitro studies were 
well tolerated by mice exhibiting no acute toxic side-effects after i.v. application of plain 
polymers at a concentration of 400 µg/mL (in HBG) with 100 µg pseudodendrimer applied 
per 20 g mouse.  
 
Both compounds were then tested for their in vivo gene transfer efficiency in a s.c. Neuro2a 
tumor model. The experiments were conducted by intravenous injection of complexes of 
G2-HD-OEI and G3-HD-OEI (c/p-ratio 1 and 2) using luciferase (pEGFPLuc) as reporter 
gene. Complexes were prepared at a final DNA concentration of 200 µg/mL in HBG with 
50 µg DNA applied per 20 g mouse. Control mice were HBG buffer treated. Mice receiving 
polyplexes showed no signs of acute toxicity after application and polyplexes were well 
tolerated. 24 h after injection, no significant loss of body weight was observed for G2-HD-OEI 
polyplexes at a c/p-ratio of 1 whereas G3-HD-OEI polyplexes resulted in 5% loss of body 
weight. C/p-ratio 2 caused a body weight loss of 8 – 9% for both polymers. 
 
Fig. 28 presents luciferase reporter gene expression in main organs and tumor tissue 24 h 
after i.v. application of polyplexes. All polyplexes at both c/p-ratios led to transgene 
expression that was predominantly found in tumor tissue. Notably, luciferase tumor levels 
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were as high as reported for standard polycations like e.g. LPEI in the same tumor model as 
depicted in Fig. 18. 
 
Fig. 28: Luciferase gene expression 24 h after i.v. administration of G2-HD-OEI or G3-HD-OEI 
in A/J mice bearing Neuro2a s.c. tumors. C/p-ratios 1 and 2 were investigated. Buffer (HBG) 
treated mice were used as control. Luciferase gene expression is presented as relative light units per 
organ or tumor, respectively (RLU / organ) (mean ± SD, n = 8 animals per group). Tumor weights 
ranged between 300 mg and 400 mg. Two nanograms of recombinant luciferase correspond to 107 
light units.  
(ANOVA, Duncan’s test , * p < 0.05 for G2-HD-OEI vs. G3-HD-OEI c/p-ratio 1) 
 
The “golden standard” LPEI is known for its highest transgene expression level (see Fig. 18) 
in mice mainly found in the lung after i.v. application, which is also responsible for toxic side-
effects of this polymer (tumor / lung ratio < 0.01).17,18,72 In contrast, G2-HD-OEI and 
G3-HD-OEI resulted, notably, at all investigated c/p-ratios in much lower luciferase gene 
expression in lung tissue. Importantly, in case of G3-HD-OEI the most favorable high 
tumor / lung ratio of 89 was found at c/p-ratio 1. The lower tumor / lung ratio of 15 at 
c/p-ratio 1 in case of G2-HD-OEI is due to the lower tumor transfection level at this c/p-ratio. 
At c/p-ratio 2 both compounds exhibited tumor / lung ratios of about 20 at similar high 
transgene expression level in tumor tissue while an increase in liver, spleen, heart and lung 
tissue compared to c/p-ratio 1 was observed.  
 
Furthermore, this study demonstrated a clear influence of the dendrimer generation within 
the conjugates on transfection efficiency in vivo. For G3-HD-OEI polyplexes, gene 
expression levels in tumor tissue were 12-fold higher (p < 0.05) as compared to G2-HD-OEI 
at c/p-ratio 1 and 2.5-fold higher at c/p-ratio 2 (see Fig. 28). 
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The biocompatibility of all polyplexes in mice was assayed simultaneously by investigating 
liver enzyme levels in serum of collected blood (AST, ALT, GLDH and AP). Buffer (HBG) 
treated mice were used as negative control. None of the formulations induced any significant 
increase of liver enzyme levels (Fig. 29). 
 
Fig. 29: Liver enzyme levels in serum 24 h after polyplex treatment. Alkaline (ALT) and aspartate 
(AST) aminotransaminases, glutamate dehydrogenase (GLDH) and alkaline phosphatase (AP) were 
determined using standard kinetic UV tests. Data represents mean values (+ SD, n = 8 animals per 
group), except for buffer treated control mice (n = 4). No significant differences in liver enzyme levels 
between control mice and polyplex treated mice were found (ANOVA, Duncan’s test). 
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3.4  Stabilization and targeting of polyplexes 
3.4.1 Lateral stabilization of HD O / DNA polyplexes  
Stabilization of polyplexes using lateral reversible crosslinking strategies after complex 
formation could be a promising tool to overcome the undesired instability of complexes in 
presence of serum proteins or solutions of high ionic strength likewise under in vivo 
conditions. This conceptual approach has already been successfully shown by several 
researchers in case of HMW polycations like for e.g. BPEI44,68,73 or PLL43,66,74 polyplexes. For 
polyplexes of LMW oligoamines this idea might be especially beneficial as their lower charge 
density results in less tightened particles leading to a higher susceptibility of them against 
polyelectrolytes and solutions of high ionic strength. Thus, lateral stabilization to increase the 
colloidal stability of polyplexes was investigated here using of the LMW pseudodendritic 
oligoamine HD O. 
 
3.4.1.1 Synthesis of stabilized polyplexes 
As indicated in Fig. 30, two different crosslinkers were investigated for lateral stabilization of 
polyplexes: first, dithiobissuccinimidyl propionate (DSP), a homobifunctional 
N-hydroxysuccinimide (NHS) ester that contains a bioreducible disulfide bond, which can 
break down in reductive environment e.g. in the cytoplasm due to a higher gluathionine level 
compared to the extracellular compartment. And second, its non-reducible counterpart 
disuccinimidyl suberate (DSS) as stable crosslinker, used for control studies. 
 
Both DSP and DSS reacted in an electrophilic substitution reaction with primary amines of 
HD O by forming stable covalent amide bonds. The crosslinking reaction proceeded under 
optimized conditions, as described in literature, for 30 minutes at room temperature.44 For 
crosslinking, the following different molar ratios of crosslinker to amine were chosen: 0.05, 
0.06 and 0.07. These ratios were used since initial physicochemical studies of laterally 
stabilized HD O polyplexes prepared at higher crosslinker / amine ratios demonstrated 
formation of undesired huge and multimodal particles, most probably due to intermolecular 
side-reactions. Nevertheless, one can assume that at the chosen ratios of crosslinker to 
HD O amine (0.05; 0.06 and 0.07) only 30 - 50% of primary amines of HD O are converted 
by the reaction with DSP or DSS. However, the residual primary amine content might be 
useful for further modification of the stabilized polyplexes with e.g. targeting ligands like 
transferrin (Tf) or polyethylenglycol (PEG) as shielding domain. 
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Fig. 30: Schematic illustration of HD O / DNA crosslinked polyplexes. Reaction scheme for the 
conversion of HD O with dithiobis (succinimidyl propionate) (DSP) or disuccinimidyl suberate (DSS). 
Different ratios of crosslinker to primary amine groups were investigated ranging form 0.05 to 0.07. 
 
3.4.1.2 Physicochemical characterization of stabilized polyplexes 
The first objective was to evaluate the influence of the surface crosslinking of HD O 
complexes on their physicochemical properties. Beside HD O / DNA polyplexes, also 
polyplexes of BPEI were investigated in parallel to allow a comparison to a branched, but not 
hydrolysable cationic structure within polyplexes. 
 
Table 7 summarizes the basic studied biophysical characteristics of crosslinked HD O / DNA 
complexes formed at a c/p-ratio of 1 [w/w]. For size and zeta-potential measurements, 
polyplexes were prepared in HBG. Subsequently, they were crosslinked by the addition of 
the appropriate amount of DSP or DSS stock solution to generate the desired crosslinking 
degree. For the investigation of uncrosslinked HD O / DNA polyplexes HBG was added 
instead of the crosslinker. Uncrosslinked polyplexes resulted in a hydrodynamic diameter of 
about 190 nm, which is in good agreement to previous studies. The introduction of linking 
agents to the polyplexes – either using DSP or DSS – influenced particle sizes of HD O 
polyplexes only moderately; thus, hydrodynamic diameters were ranging between 150 nm 
and 220 nm for all degrees of crosslinker / amine. Also the surface charge was only 
marginally affected, retaining a comparable zeta-potential of about +30 mV. 
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Table 7: Effect of lateral stabilization using DSP or DSS. Crosslinkers were used at indicated molar 
ratios upon HD O / DNA polyplexes that were prepared at a c/p-ratio of 1. All measurements were 
performed in three independent experiments. 
 
In case of BPEI, used at a c/p-ratio of 0.8, similar results were found (data not shown). The 
original size of uncrosslinked BPEI/DNA polyplex was 120 nm (± 6nm). Polyplex sizes 
ranged between 100 nm and 150 nm after lateral stabilization at all crosslinking degrees 
using either DSP or DSS. Stabilized BPEI polyplexes resulted in zeta-potentials around 
+30 mV, although in case of DSP a slight decrease of the surface charge was found with an 
increasing ratio of crosslinker / amine (ratio 0.00: +31 mV; ratio 0.05: +30 mV; ratio 0.06: 
+26 mV, ratio 0.07: +23 mV).  
 
A simple means to measure stabilization of polyplexes is to evaluate their susceptibility to 
disruption by polyelectrolytes such as heparin, determining the release of free DNA by 
electrophoresis.  
 
Using this approach, at first the sensitivity of uncrosslinked polyplexes toward polyanions of 
HD O was investigated. By titration studies it was found that the use of 0.25 I.U. heparin 
resulted in a complete release of DNA from the HD O complex (Fig. 31) indicating that the 
non-crosslinked polyplex is completely unstable at this and higher concentrations. Similar 
results were also obtained for BPEI (data not shown). 
 
Fig. 31: DNA compacting ability of HD O after incubation with different amounts of heparin. 
HD O / DNA polyplexes were prepared at a c/p-ratio of 1. The release of free DNA following 0.5 h of 
incubation with increasing amounts of heparin was investigated by gel shift assay. (A) DNA, (B) w/o 
heparin, (C) 0.05 I.U., (D) 0.1 I.U., (E) 0.25 I.U., (F) 0.5 I.U., (G) 0.75 I.U., (H) 1.0 I.U.. 
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Within the investigations on the susceptibility of laterally stabilized polyplexes against 
heparin, it was observed that HD O and BPEI complexes could be strengthened against 
polyelectrolyte exchange reactions by crosslinking with DSP or DSS. This was demonstrated 
in Fig. 32 and Fig. 33 by the retention of these complexes in the well using 0.25 I.U. heparin 
at all three investigated crosslinker / amine ratios (for HD O: see Fig. 32, lanes F, G and H; 
for BPEI: see Fig. 33, lanes C, D, E). Moreover, also an increase of the heparin 
concentrations up to 1.0 I.U. heparin was not able to challenge the tightened complexes 
resulting in no release of free DNA (data not shown). 
 
 
Fig. 32: Stability of crosslinked HD O polyplexes against polyanionic exchange reactions using 
heparin. HD O / DNA polyplexes were prepared at a c/p-ratio of 1. Polyplexes were crosslinked using 
DSP (left) or DSS (right) at crosslinker / amine ratios of 0.05; 0.06 and 0.07. The release of the DNA 
was determined by gel electrophoresis 0.5 h after incubation of polyplexes with 0.25 I.U. heparin. DTT 
was used to demonstrate the reversibility of lateral stabilization in case of DSP- vs. DSS-crosslinked 
polyplexes. For this, after 30 min DTT (25 mM) incubation, 0.25 I.U. heparin was added and 
proceeded as described above. Lanes A-I (in each picture) represent: DNA (A and I); without 
crosslinker (B); ratio 0.05 plus DTT (C); ratio 0.06 plus DTT (D); ratio 0.07 plus DTT (E); ratio 0.05 w/o 
DTT (F); ratio 0.06 w/o DTT (G); ratio 0.07 w/o DTT (H). 
 
 
Fig. 33: Stability of crosslinked BPEI polyplexes against polyanionic exchange reactions using 
heparin. BPEI / DNA polyplexes were prepared at a c/p-ratio of 0.8 (representing an N/P-ratio of 6). 
Polyplexes were crosslinked using DSP (left) or DSS (right) at crosslinker / amine ratios of 0.05; 0.06 
and 0.07. The release of the DNA was determined by gel electrophoresis 0.5 h after incubation of 
polyplexes with 0.25 I.U. heparin. DTT was used to demonstrate the reversibility of lateral stabilization 
in case of DSP- vs. DSS-crosslinked polyplexes. For this, after 30 min DTT (25 mM) incubation, 
0.25 I.U. heparin was added and proceeded as described above. Lanes A-I (in each picture) 
represent: DNA (A and I); without crosslinker (B); ratio 0.05 w/o DTT (C); ratio 0.06 w/o DTT (D); ratio 
0.07 w/o DTT (E); ratio 0.05 plus DTT (F); ratio 0.06 plus DTT (G); ratio 0.07 plus DTT (H). 
 
3 Results  64 
 
The possibility to reverse the stabilization of the crosslinked polyplexes was demonstrated by 
treating DSP and DSS-linked complexes with the reducing agent DTT. This led, in case of 
DSP stabilized polyplexes due to cleavage of the disulfide bonds, to destabilized complexes 
where heparin caused a release of free DNA (Fig. 32, for HD O: see Fig. 32 ‘DSP’ lanes C, 
D, E; for BPEI: see Fig. 33 ‘DSP’ lanes F, G, H). In contrast, DSS-crosslinked polyplexes 
were retained stabilized as the complexes remained in the wells and no free DNA could be 
detected in the gel. 
An alternative method to monitor the enhanced stability of complexes is to investigate their 
susceptibility against sodium chloride (NaCl) induced polyplex dissociation following the 
method as described in section 3.3.2.2. 
 
 
Fig. 34: Colloidal stability of DSP- or DSS-crosslinked HD O polyplexes in presence or absence 
of DTT. A) uncrosslinked HD O polyplex at a c/p-ratio of 1; B) DSP-crosslinked HD O polyplexes; C) 
DSS-crosslinked HD O polyplexes. The stability of polyplexes against dissociation with NaCl was 
monitored by detecting changes in the intensity of scattered light as a function of an increasing NaCl 
concentration. The susceptibility against NaCl in absence (solid lines) and presence of DTT (dashed 
lines) is presented. Values represent the mean ± SD out of three independent measurements. 
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Fig. 34 and Fig. 35 show the intensities of scattered light of the polyplexes as a function of 
the sodium chloride concentration.  
 
Using non-crosslinked HD O polyplexes (Fig. 34A) the scattering intensity decreased at a 
NaCl concentration of 0.75M upwards, suggesting dissociation of the complex to free DNA 
and polycation. But, when HD O polyplexes have reacted with either DSP or DSS at the 
different ratios of crosslinker / amine, a shift of the point of disassembly to higher NaCl 
concentrations was found. By this, it is quite obvious that due to the stabilization reaction, 
DNA cannot dissociate out of the polyplexes, because HD O became crosslinked upon the 
surface forming a continuous net surface network encaging the nucleic acid payload 
(Fig. 34). 
 
 
Fig. 35: Colloidal stability of DSP- or DSS-crosslinked BPEI polyplexes in presence or absence 
of DTT. A) Uncrosslinked BPEI polyplex at c/p-ratio of 0.8; B) DSP-crosslinked BPEI polyplexes; C) 
DSS-crosslinked BPEI polyplexes. The stability of polyplexes against dissociation with NaCl was 
monitored by detecting changes in the intensity of scattered light as a function of an increasing NaCl 
concentration. The susceptibility against NaCl in absence (solid lines) and presence of DTT (dashed 
lines) is presented. Values represent the mean ± SD out of three independent measurements. 
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In case of BPEI a higher colloidal stability was already found for the unstabilized complex as 
shown in Fig. 35A. Most probably this is caused by the in molecular weight larger BPEI 
molecule resulting in an increased strength of its electrostatic interaction with DNA and 
consequently tighter DNA binding. Thus, an obvious effect of crosslinking via DSP or DSS 
did not significantly enhance the colloidal stability of BPEI polyplexes in the investigated 
sodium chloride concentration range (Fig. 35). Although the results found after DTT 
incubation seemed to be contradictionary (Fig. 35B and C) since a decrease of the 
scattering intensity was detected, it can be assumed that during the crosslinking reaction 
using DSP or DSS the number of primary amine functionalities upon the surface of BPEI 
polyplexes was reduced. This decrease already led to a destabilizing effect of the polyplexes 
as electrostatic interactions for DNA compaction are diminished which gets obvious under 
the DTT reductive environment. 
 
For compound HD O the reversible stability of the crosslinked polyplexes could be shown in 
these studies again using DTT to simulate a reducing environment. The course of both 
curves either in presence or absence of DTT was similar. Importantly, the incubation of DTT 
alone did not affect complex stability since uncrosslinked polyplexes of HD O showed the 
same pattern of scattering intensity in presence or absence of DTT (Fig. 34A). It was 
observed that in all cases of DSP-linked polyplexes a significant decrease of scattering 
intensity was found after DTT incubation (Fig. 34B). This can be attributed to a removal of 
the stabilization of the polyplexes due to the break-down of the disulfide bonds resulting in 
disassembly of the polyplexes. For comparison, the DSS-crosslinked polyplexes remained 
stable, which was indicated by the similar pattern of the curve progression in presence or 
absence of DTT (Fig. 34C). Hence, these results again strongly suggest that DSP surface 
stabilization can be removed under a reducing environment, and DNA could be released 
efficiently from the polyplex whereas DSS stabilization, in contrast, led to permanently stable 
polyplexes. 
 
3.4.1.3 Effect of stabilization of polyplexes on reporter gene expression in vitro 
It is important that the increased stability of the crosslinked polyplexes does not prevent 
transgene expression within the cells or within the target tissue. Therefore the consequences 
of lateral stabilization on both polyplexes, HD O versus BPEI were examined in four different 
cell lines. In vitro transfection studies were carried out as described above using pCMVLuc 
as reporter gene in K562 cells (human chronic myeloid leukemia), Neuro2a cells (murine 
neuroblastoma), B16F10 cells (murine melanoma) and PC3 cells (human prostate cancer). 
LPEI (22 kDa) polyplex (prepared in HBG) was used as positive control at the optimized c/p-
ratio of 0.8 (corresponding to an N/P-ratio of 6). 
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Fig. 36 shows the transfection efficiency and cytotoxicity pattern of all DSP- or DSS-
crosslinked polyplexes of both polycations. Generally, uncrosslinked HD O and BPEI 
particles resulted in similar good transfection efficiencies in all four investigated cell lines and 
exhibited reporter gene expression levels similarly high as found for the “golden standard” 
LPEI. 
 
Fig. 36: Reporter gene expression of laterally stabilized BPEI (c/p-ratio 0.8) and HD O 
(c/p-ratio 1) polyplexes. A) K562 (125000 cells per well), B) Neuro2a (10000 cells per well), C) 
B16F10 (5000 cells per well) D) PC3 (5000 cells per well). Cell numbers indicated cells/well at the 
point in time of cell plating. Polyplexes were formed using the described procedure in HBG; LPEI was 
applied as positive control at the optimized N/P-ratio of 6 which represents a c/p-ratio of 0.8. Dark 
solid bars indicate uncrosslinked polyplexes; bright solid bars represent DSS-linked particles at 
indicated crosslinking degrees; crossbred bars indicate DSP-linked particles at indicated crosslinking 
degrees. On left side, transfection efficiency is expressed as RLU / well and shown as the mean 
(± SD) out of three independent measurements, each performed in triplicates. On the right side, 
metabolic activity of cells 24 h after transfection is demonstrated; this was performed in parallel 
experiments. 
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A distinct difference between HD O and BPEI regarding their transfection efficiency was 
detected in terms of the crosslinked particles: in case of BPEI, lateral stabilization of 
polyplexes always led to a significant reduction of transfection efficiency, whereas for HD O 
polyplexes lateral stabilization resulted in only marginal declines or even a slight 
enhancement of the transfection levels. Furthermore, for BPEI a dependency between the 
degree of crosslinking and the transfection level was found showing that the reporter gene 
expression decreased as a function of an increasing molar ratio of DSS or DSP. This is in 
good accordance to similar findings as previously described.44,66,68 For HD O polyplexes such 
a dependency was not detected. Nevertheless, crosslinking complexes with the disulfide 
containing bioreducible DSP resulted in polyplexes with higher transfection activity than 
crosslinking them with non-degradable DSS. This finding might be explained – not only for 
HD O but also for BPEI – by the enhanced release of DNA due to destabilization of the 
polyplexes as a result of the disulfide break-down (see section 3.4.1.2). Notably, this effect 
was more pronounced for BPEI polyplexes showing that the DSP-crosslinked particles were 
between 10- to 100-fold more efficient than DSS-linked ones. In contrast, for HD O particles 
an only 5- to 10-fold improvement was found from DSS to DSP-crosslinked polyplexes. 
Importantly, in contrast to BPEI, HD O polyplexes that were crosslinked via DSP “restored” in 
the transfection efficiency levels to the same as found for the uncrosslinked particles all 
investigated cell lines. In some cases, like e.g. in K562 cells, the transfection efficacy was 
even around 10-fold enhanced for all three crosslinking degrees. However, it has to be 
considered that this can be also attributed to the improved cytotoxicity profile of the DSP-
linked polyplexes compared to the DSS-linked ones in K562 cells. Generally, lateral 
stabilization of particles did not significantly influence the metabolic activity of cells (see 
Fig. 36, right panels). 
 
To investigate whether the lateral stabilization of HD O polyplexes may have an influence on 
their transfection kinetics, luciferase gene expression levels were followed over time. Fig. 37 
shows the time course of gene expression after transfection using stabilized HD O c/p-ratio 1 
polyplexes in Neuro2a cells crosslinked via DSP (Fig. 32A) or DSS (Fig. 32B) at the 
indicated molar ratios of crosslinker to amine. LPEI and BPEI polyplexes at their optimized 
c/p-ratio of 0.8 (representing an N/P-ratio of 6) were followed over time as control. The 
unstabilized HD O complex and also both LPEI and BPEI polyplexes resulted in a step by 
step decrease of reporter gene expression already 48 h post-transfection that was continued 
within the following days. Thus, transfection efficiency of the unstabilized HD O polyplex 
decreased more than 150-fold within the investigated time course of 24 h to 96 h post-
transfection. In a similar manner, the transfection of LPEI and BPEI polyplexes decreased 
time-dependently even though the rough drop down as found for HD O between 24 h and 
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48 h post-transfection was not detected. This rapid decrease may be partially attributed to 
the ester degradability of HD O. In contrast, the stabilized HD O polyplexes, both DSP- or 
DSS-crosslinked, resulted in a permanent luciferase reporter gene expression over time that 
was kept at similar high levels as 24 h after transfection. Importantly, the bioreversibly 
crosslinked DSP polyplexes were more efficient and resulted in higher reporter gene 
expression levels than the DSS-linked compounds. 
 
Taken together, these in vitro results highlighted i) the importance of using bioreversible 
crosslinking agents that provide an extracellular stability of the complexes followed by an 
enhanced release of DNA in e.g. reductive intracellular environment and ii) the advantage of 
lateral stabilization of the labile HD O polyplex, making this particle formulation very 
interesting for further investigations in terms of developing optimized polyplexes toward a 
“synthetic virus”. 
 
Fig. 37: Reporter gene expression levels in Neuro2a cells over time. Neuro2a cells were 
transfected with unmodified HD O at a c/p-ratio of 1 or stabilized polyplexes at indication 
crosslinker / HD O amine degree. The reporter gene expression level of DSP-crosslinked particles A) 
and DSS-crosslinked particles B) are shown. LPEI and BPEI polyplexes at their optimized N/P-ratio of 
6 (c/p-ratio 0.8) were included for comparison. Polyplexes were prepared in HBG. Data expressed as 
mean values (± SD) out of three independent experiments each performed in triplicates. Two 
nanograms of recombinant luciferase correspond to 107 light units. 
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3.4.1.4 Effect of laterally stabilized polyplexes on gene expression after intratumoral 
administration 
Due to the promising data found in the in vitro studies, the best performing laterally stabilized 
HD O polyplexes were further investigated for their in vivo gene transfer in tumor tissue. In 
these studies, HD O particles formed at a c/p-ratio of 1 were stabilized at crosslinking 
degrees of 0.05 using both DSP and DSS. The experiments were conducted by intratumoral 
injection into subcutaneous neuroblastoma tumors in A/J mice. Uncrosslinked HD O polyplex 
was used as reference for comparison. All particles were prepared at a final DNA 
concentration of 200 µg/mL (pEGFPLuc) in HBG. Mice receiving 100 µL polyplex solution per 
tumor showed no signs of toxicity.  
 
 
Fig. 38: Reporter gene expression of laterally stabilized and uncrosslinked HD O polyplexes in 
vivo after i.t. application. Measurements were conducted using the IVIS system for evaluation. 
Luciferase gene expression is presented as total flux (photons / sec) in tumor tissue (mean ± SD, 
n = 6 tumors per group). Tumor sizes ranged between 6 and 10 mm in diameter. HD O represents 
values for uncrosslinked HD O polyplexes (c/p-ratio 1); DSP 0.05 shows values for HD O (c/p-ratio 1) 
crosslinked via DSP at a molar ratio of DSP / HD O amine; DSS 0.05 shows values for HD O (c/p-
ratio 1) crosslinked via DSS at a molar ratio of DSS / HD O amine.  
(ANOVA, Duncan’s test , *** p < 0.001 for DSS 0.05 vs. DSP 0.05; * p < 0.05 for DSS 0.05 vs. DSP 
0.05; ♦♦♦ p < 0.001 for DSP 0.05 vs. HD O; ♦ p < 0.05 for DSP 0.05 vs. HD O) 
 
Fig. 38 shows the reporter gene expression kinetics after intratumoral application of 
polyplexes. All polyplexes resulted in reasonable gene expression at day 1 post 
administration that was, in case of HD O (uncrosslinked), similarly high in tumor tissue as 
observed after intravenous injection of polyplexes into tumor bearing mice. In case of the 
laterally stabilized polyplexes it was found that both stabilization strategies led to elevated 
gene expression levels in tumor tissue, irrespective of time. Thus, while gene expression of 
unstabilized HD O polyplexes resulted in a half-life of about 2.5 days, both crosslinked 
particles showed a permanent gene expression over time being always 2- to 11-fold higher 
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than the unstabilized HD O polyplex (p < 0.05). Importantly, there was a significant difference 
of the gene expression pattern between DSP-, DSS-crosslinked polyplexes and unstabilized 
particles within the first 24 h. Thus, the bioreducible, disulfide linked polyplexes (DSP 0.05) 
resulted in significantly 4-fold (p < 0.001) higher gene expression levels compared to both 
DSS-linked (ratio 0.05) and uncrosslinked ones.  
 
 
3.4.2 Transferrin (Tf)-targeting of lateral bioreversibly stabilized 
polyplexes 
In previous investigations using transferrin (Tf) it was shown that the incorporation of this 
targeting ligand can increase the specificity of polyplexes toward tumor cells.52,75,76 In 
preliminary studies following the standard protocol for preparation of targeted polyplexes by 
simply mixing e.g. Tf-BPEI with a polycation like LPEI, it was found in case of HD O that the 
resulting complexes led to huge particles that tended to aggregate in presence of salt (data 
not shown). This may end up in the disassembly of the polyplexes under physiological 
conditions, which is very undesirable with regard to both in vitro and in vivo application. To 
counter this, the formation of laterally stabilized HD O complexes as described above may 
provide a good opportunity for preparation of Tf-targeted HD O polyplexes that may remain 
stable under physiological conditions – being a prerequisite for systemic targeted gene 
delivery using HD O in terms of a “synthetic virus” system. 
 
 
 
Fig. 39: Scheme for the incorporation of transferrin (Tf) as targeting ligand. DSP stabilized 
HDO / DNA particles are coated with oxidized transferrin. Due to an excess of primary amine bonds 
ever and anon meta-stable imine bonds are formed coating the particle. 
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3.4.2.1 Preparation and physicochemical characterization of Tf-targeted HD O 
polyplexes 
A series of Tf-targeted HD O polyplexes was formed by addition of either oxidized or un-
oxidized transferrin to stabilized HD O polyplex formulations (based on c/p-ratio 1) 
(see Fig. 39). In the following studies only DSP-crosslinked particles were investigated 
because of their more favorable in vitro characteristics (Fig. 36) as well as due to the 
promising in vivo data after i.t. administration (Fig. 38). After lateral stabilization of particles, 
3.5% transferrin [w/w] (Tf / HD O) in its oxidized or unoxidized form (Tfox or Tfunox) was added 
in order to coat the particles with the targeting ligand. In preliminary studies (data not shown) 
it was found that the incorporation of 3.5% transferrin resulted in optimized physicochemical 
properties for the investigated polyplexes. The oxidized form of transferrin contains aldehyde 
groups that may react with the remaining primary amino groups upon the DSP stabilized 
polyplexes to form imine bonds. Imine bonds are reversible in theory, but are assumed to be 
sufficiently stable in the current case because of the large local excess of polyplex amines. 
Hence, transferrin will be always “entrapped” by neighboring primary amines. In 
consequence, this may lead to small sized and also partially shielded particles. Unoxidized 
transferrin was used for control studies.  
 
Table 8 summarizes the basic physicochemical characteristics of all studied polyplexes, 
based on DSP stabilized HD O polyplexes at crosslinking degrees of 0.05, 0.06 and 0.07. 
Interestingly, only the polyplexes that were adopted from stabilized particles in a crosslinking 
degree of 0.05 and 0.06 resulted in small particle sizes while a linker / amine ratio of 0.07 
gave huge aggregates; Tf-coated HD O polyplexes (Tfox or Tfunox) with a crosslinking degree 
of 0.05 and 0.06 resulted in particle sizes of 160 nm to 200 nm with a PDI ranging around 
0.25. For comparison, the unstabilized HD O polyplexes resulted in all cases in aggregates, 
indicating the importance of lateral stabilization of LMW polyplexes prior to incorporation of 
the targeting ligand. 
 
Importantly, there was a difference found regarding the measured zeta-potentials. Thus, only 
the oxidized form of Tf led to shielding effects (+14 mV) also indicating by this that the 
coating reaction using transferrin has worked, while Tfunox did not reduce the detected zeta-
potential as compared to non-targeted HD O complexes. In both latter cases zeta-potentials 
were ranging around +20 mV to +25 mV. Thus, although both forms of Tf can endow small 
particle sizes, shielding and steric stabilization can only be achieved using the oxidized form 
of transferrin. 
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Table 8: Hydrodynamic diameters of Tf-targeted stabilized polyplexes. Complex sizes were 
determined in HBG using by dynamic light scattering at a DNA concentration of 10 µg/mL. For zeta-
potential measurements polyplexes were diluted 1:5 with HBG to a final DNA concentration of 
2 µg/mL. Mean values (± SD) out of three independent measurements are shown. 
 
 
3.4.2.2 Biological characterization of Tf-targeted polyplexes 
After determination of the transferrin receptors upon K562 and Neuro2a cells using FACS 
analysis (99% of Neuro2a cells and 89% of K562 cells were TfR positive), transgene 
expression levels using Tf-targeted HD O polyplexes were investigated in both cell lines. 
Transfection efficiency (luciferase assay) and cytotoxicity (MTT assay) of the formed 
particles were evaluated in parallel using pCMV-Luc as reporter gene (DNA concentration 
20 µg/mL). Studies were performed in the presence of 10% fetal calf serum at 4 h interaction 
time of the polyplexes with cells. For LPEI, taken as reference in all experiments, a c/p-ratio 
of 0.8 was used (N/P-ratio of 6). 
 
In these studies the effect of the incorporation of Tf (Tfunox or Tfox) was investigated only using 
stabilized polyplexes at a crosslinking degree of 0.05 and 0.06 since the DSP / amine ratio of 
0.07 resulted in aggregation after incorporation of Tf within polyplexes. Although the 
unstabilized HD O polyplex also “spiked” with transferrin showed aggregation these 
formulations were investigated for comparative studies.  
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Fig. 40: TfR-targeting using different Tf-coated particles based on stabilized HD O polyplexes. 
Neuro2a A) and K562 B) cells were transfected with unmodified HD O or stabilized HD O polyplexes 
using the indicated oxidation forms of Tf. LPEI polyplexes at their optimized N/P-ratio of 6 (c/p-ratio 
0.8) were included for comparison. Polyplexes were prepared in HBG. Data expressed as mean 
values (± SD) out of three independent experiments each performed in triplicates. Two nanograms of 
recombinant luciferase correspond to 107 light units. Metabolic activities after transfection as 
determined by MTT assay are shown in the right panels. 
Fig. 40 depicts the reporter gene expression levels 24 h post transfection in Neuro2a and 
K562 cells. Transfection levels of unstabilized HD O polyplexes either un- or Tf-targeted 
(Tfunox or Tfox) resulted in similar high reporter gene expression levels in both cell lines and 
thus no ligand-induced increase of transfection could have been detected; most probably this 
was due to aggregate formation followed by polyplex destabilization and disassembly during 
transfection. In case of the stabilized particles at a crosslinking degree of both 0.05 and 0.06, 
distinct differences with regard to the investigated Tf formulations were found. Thus, only if 
the oxidized form of transferrin was used for coating particles an enhanced transfection 
efficiency level could be found whereas the reporter gene expression level using Tfunox 
remained similarly high as found for the untargeted stabilized polyplexes. The latter effect 
might have been also due to a rather unstable particle formulation upon Tfunox addition 
leading to the same effect as described above for the unstabilized HD O particles. 
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Importantly, the described transfection pattern was detected in Tf-receptor expressing cell 
lines, Neuro2a and K562. Hence, in Neuro2a cells, an about 10-fold increase from 
HD O / 0.05 to HD O / 0.05 / Tf (3.5%) was found. Similarly, in K562 cells an 8-fold increase 
for the same formulations indicated enhanced transfection efficiency due to the transferrin 
receptor targeting effect. Notably, none of the investigated polyplexes induced any decrease 
of metabolic activity of cells after transfection making these formulations very interesting for 
further investigations in the context of the establishment of “synthetic viruses”.  
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4 Discussion 
Gene therapy offers a promising tool for treating various forms of cancer and a number of 
inherent diseases although the clinical use is still mainly restricted due to the lack of safe and 
efficient gene delivery systems.2 Synthetic gene carriers, including polycations, liposomes 
and polypeptides might be advantageous due to pharmaceutical issues such as low cost of 
synthesis and easy scale-up, but they show poor transfection efficiency levels in comparison 
to their viral counterparts.77,78 Thus, an excellent transfection activity at low toxicity both in 
vitro and in vivo should be the major considerations regarding the design of novel degradable 
synthetic gene delivery devices. Recently, many of such polymers have been 
generated35,37,79-87 aiming to reduce toxicity while maintaining transfection efficiency levels 
comparable to “golden standard” vectors like PAMAM dendrimers41,88 or optimized 
polyethylenimines.89,90  
4.1 Development of degradable pseudodendritic oligoamines 
The aim of this thesis was to synthesize a novel class of biodegradable synthetic gene 
delivery carriers that show low toxic effects at gene expression levels comparable to 
commonly used standard BPEI and LPEI for in vitro and in vivo DNA gene delivery.  
 
4.1.1 Synthesis and structural characterization of pseudodendrimers 
Degradable random polymers based on low molecular weight (LMW) oligoamines were 
previously described by several researchers.32,81,83,91-93 For example, promising results have 
been obtained81,83 by coupling low molecular weight oligoethylenimine 800 Da (OEI) with 
short diacrylate linkages, thus combining the beneficial low cytotoxic properties of OEI with 
the superior transfection efficiency of higher molecular weight polyethylenimines. The 
hydrolysis of the ester bonds may occur under physiological conditions and the encouraging 
low toxicity found was correlated to this degradation behavior.81,83 A technical weakness of 
this polymer approach was the polydispersity of the resulting compounds, i.e. the 
heterogeneity in molecular weight, which was inherent to the applied procedure in polymer 
synthesis. The design of dendrimers is an elegant solution to obtain well-defined polymers 
with narrow molecular weight distribution. As an example, PAMAM dendrimers have already 
successfully been applied for gene delivery.39,41 
In the current work better defined low molecular weight pseudodendritic oligoamines were 
designed, starting with either oligoethylenimine 800 Da (OEI) or polypropylenimine 
dendrimers (PPI) as core building blocks. Different dioldiacrylates, which contain 
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hydrolysable ester bonds, were used to form dendritic branches and various oligoamines to 
modify the conjugates were added to generate a versatile family of pseudodendrimers. 
Although the OEI core based conjugates did not exhibit the typical dendritic structure based 
on a symmetric core unit, they followed the dendritic concept due to their branched 
organization, assembled by adding a generation of monomer onto a core unit.38 An 
improvement toward better defined pseudodendrimers was achieved in the next 
development step by using the symmetric polypropylenimine dendrimer PPI instead of the 
randomly branched OEI as core building block. Synthesis procedures retained the same as 
for the OEI core based pseudodendrimers. 
 
The compounds based on OEI were used for structure-activity relationship studies to define 
structural components within pseudodendrimers that lead to high transfection efficiency at 
low cytotoxicity. PPI core based pseudodendrimers were investigated to compare the 
influence of the dendrimer generation within the core unit on biophysical and biological 
properties of the resulting derivatives. Furthermore, the latter studies emphasized the 
importance of ethylenimine moieties within pseudodendrimers for efficient gene delivery.  
 
All in all, 17 different OEI core based and 4 different PPI core based pseudodendrimers were 
synthesized. According to 1H NMR analysis and GPC measurements, it was found that the 
applied synthesis procedure always resulted in branched, low molecular weight 
pseudodendrimers (4000 – 8000 Da) containing high rates of hydrolysable ester bonds 
(around 90% of ester bonds remained after synthesis and purification). Moreover, all 
conjugates showed a narrow molecular weight distribution with PDIs ranging between 1.5 
and 2.5 for the most potent pseudodendrimers (see Table 3 and Table 5) demonstrating the 
improvement toward better defined conjugates using the synthesis procedure established 
here. 
 
4.1.2 Degradation behavior of pseudodendrimers 
The degradability of gene delivery polymers to non-toxic monomers is desired in terms of 
developing suitable polyplex formulations for clinical application. Besides this, either a site-
specific or time-dependent degradation leading to polyplex destabilization and an improved 
DNA release at the target site is worthwhile.  
 
There is still a lack of feasible methods to proof degradation within the organism and 
therefore it became necessary to imitate the physiological environment (pH and temperature) 
in vitro. Several techniques to follow polymer degradation can be used like for instance size 
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exclusion chromatography (SEC)83,94, mass spectroscopy (MS)95 or nuclear magnetic 
resonance spectroscopy (NMR)18,81.  
HD O and the PPI core based pseudodendrimers were investigated according to their 
degradation behavior in vitro using 1H NMR spectroscopy. In case of HD O, it was found that 
after about 3 days at physiological pH 7 and 37 °C approximately 50% degraded in aqueous 
medium and after about 7 days almost no residual ester bonds were found. Similarly, both 
oligoethylenimine grafted PPI dendrimers G2-HD-OEI and G3-HD-OEI resulted in a half-life 
of about 3 days. It was obvious that the OEI grafted derivatives, G2-HD-OEI and G3-HD-OEI, 
degraded much faster under physiological conditions than the polypropylenimine grafted 
ones, G2-HD-G2 and G3-HD-G2 (t1/2 > 14 days). It is likely that the lower water solubility of 
the latter compounds due to the more hydrophobic G2 moieties upon the surface reduced 
ester hydrolysis, thus increasing their half-life. Altogether the found degradation behavior of 
the investigated pseudodendrimers is in good accordance to results reported by other groups 
concerning the degradation of poly(ester amine)s.18,37,79,95 
 
4.2 Pseudodendritic oligoamines: what’s needed for efficient DNA 
gene delivery – a study on the structure-activity relationship  
In the described studies on structure-activity relationships using the various OEI core based 
pseudodendrimers, influences on biophysical and biological properties due to 
pseudodendritic core characteristics and the different surface modifications were found. 
Hence, these investigations gave an idea which features were essential to achieve satisfying 
physicochemical characteristics of polyplexes as well as of attributes needed to reveal 
highest transfection efficiency at lowest cytotoxicity.  
 
4.2.1 Structural requirements of pseudodendrimers for suitable 
physicochemical characteristics 
A key requirement for efficient gene transfer using synthetic gene delivery systems is their 
ability of DNA compaction to nano-sized particles suitable for efficient cell entry. 
 
As the DNA compacting ability of polymers is strongly influenced by charge density, 
molecular weight96 and hydrophobic/-philic interactions of the polycations with DNA, studies 
on the DNA binding ability of pseudodendrimers provided information about i) the general 
utilization of these conjugates as gene transfer devices and ii) the influences of both core 
characteristics and surface modification on DNA compaction. A suitable and fast method to 
determine this is the use of the ethidium bromide exclusion assay65, which monitors 
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polycation/DNA interaction as a function of increasing c/p-ratios by following the decrease of 
fluorescence intensities. 
DNA binding experiments to investigate the attributes needed for efficient nucleic acid 
compaction revealed that an increasing hydrophobicity of the pseudodendritic core plays an 
important role in DNA compaction. This is consistent with previous work by Zhong et al. who 
found that among their linear poly(ester amine)s investigated the most hydrophobic ones 
showed the best DNA binding ability.95 Similar results were also detected by Zugates and 
colleagues in their studies on end-modified poly(beta-amino)esters.97-99 Furthermore, it was 
obvious that an increasing number of nitrogens per coupled oligoamine on the 
pseudodendritic surface resulted in stepwise rising zeta-potentials, which consequently led to 
enhanced DNA binding and subsequent DNA compaction to nano-scaled polyplexes (see 
Table 4 and Fig. 9). This effect was irrespective of the investigated pseudodendritic core and 
thus independent of core characteristics. However, these investigations also demonstrated 
that the surface modification of the pseudodendrimers containing more than 18 nitrogens per 
modification unit were able to mask the influence of core characteristics as it was 
demonstrated for HD O and compounds like HD O1200 and HD O1800 (data not shown). 
 
Hydrodynamic diameters of polyplexes were determined using dynamic light scattering 
(DLS). All OEI core based pseudodendrimers, except for the ethanolamine surface modified 
ones, resulted in small complex sizes that were ranging between 100 nm and 250 nm. PDIs 
demonstrated a low- to mid-ranged polydispersity of the resulting complexes. Hence, all the 
polyplexes were small enough and suitable for efficient cellular uptake by endocytosis.100 
 
4.2.2 Structural requirements of pseudodendrimers for optimized 
biological activity 
Reduced toxicity is undoubtedly one of the most important issues with regard to in vitro and 
in vivo application of synthetic gene carriers, but at the same time high transfection efficiency 
levels should be achieved. In vitro studies in different tumor cell lines showed that toxic 
effects and transfection efficiency levels of pseudodendrimers were based on both 
pseudodendritic core characteristics and the properties of the surface oligoamine used. 
Hence, decreasing pseudodendritic core hydrophobicity from HD to BD to ED core led to 
reduced cytotoxicity (see Fig. 10) but in general also to significantly decreased transfection 
efficiency that was detected for these compounds (Fig. 15). Consequently, it can be 
concluded that for efficient DNA gene delivery using pseudodendrimers a hydrophobic core 
domain is essential. This probably facilitates cellular uptake due to hydrophobic interactions 
with the cell membrane98 and may also be beneficial for endosomal release of the 
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polyplexes. Therefore, for endo-/lysosomal escape other factors besides the buffering 
capacity of the containing oligoethylenimine (“proton sponge”)13 that include hydrophobic 
interactions with endosomal membranes101 or the cationic nature of the polymers 
themselves102-104 may play an important role in mimicking the membrane-disruptive 
properties of viruses or natural lytic agents.105 According to the influences of the surface 
modification unit on cytotoxicity, it was observed that an increasing number of nitrogens per 
coupled oligoamine led to an increased toxic effect if plain conjugates were used as 
demonstrated in Fig. 11. There, it was shown that with an increasing number of nitrogens per 
coupled surface modification unit, cytotoxicity increases which might be due to unspecific 
interactions of amines with cell membranes. In contrast, if complexed with DNA, 
pseudodendrimers showed a different behavior since direct interactions were “hampered” by 
the condensed DNA and the characteristics of the resulting polyplexes determined 
cytotoxicity and transfection efficiency (Fig. 15). Thus, stepwise enhanced transfection 
efficiency with an increase of nitrogens per surface modification unit was observed for ED 
and HD core conjugates whereas BD core conjugates showed no direct correlation (also not 
in a c/p-ratio dependent manner). Furthermore, the different surface amines of HD (but not 
ED or BD) core conjugates did influence cytotoxicity. All these facts indicated that both the 
pseudodendritic core characteristics along with the surface modification within polyplexes 
play a determining role for high transfection activity at low cytotoxicity as emphasized in the 
HD core conjugate line. Hence, for example, in Neuro2a cells, cytotoxic effects increased 
from E to Sp to S and then decreased again for the OEI surface modified conjugate, while 
transfection efficiency levels increased step by step (Fig. 15). Apparently, although a 
hydrophobic HD core, which was essential for high transfection levels displayed toxic effects, 
was used, cytotoxicity of the total polyplexes seemed to be “tunable” by the surface 
oligoamine. In order to study this phenomenon in more detail, further surface oligoamines 
upon the HD core were investigated (Fig. 16). As shown, both cytotoxicity and transfection 
levels depended on an optimized balance between hydrophobic and hydrophilic domains 
within the pseudodendrimers. On the one hand, a more hydrophobic structure like HD TETA 
led to very high cytotoxicity at low transfection efficiency, similarly HD S exhibited rather high 
cytotoxicity but interestingly also high transfection levels were found (presumably due to 
better protonation and DNA binding of S over TETA). On the other hand, a purely hydrophilic 
structure such as the hydrophilic ED core conjugates resulted in low cytotoxicity but also 
moderate transfection levels. However, starting within the hydrophobic HD core line by 
increasing the number of hydrophilic ethylenimine units in the surface modification (TETA < 
PEHI < O < O1200 < O1800), the toxicity was reduced stepwise while at the same time gene 
transfer increased to an optimum level when O (i.e. oligoethylenimine 800 Da, OEI) was 
used as surface modification unit.  
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In sum, it can be considered that for efficient DNA gene delivery using pseudodendrimers a 
hydrophobic core domain is needed but it has to be in an optimal balance to the hydrophilic 
surface modification used. Finally, “tuning” of the pseudodendritic structures toward HD O 
resulted in a substantial increase of transfection efficiency at low cytotoxicity, defining HD O 
as most potent OEI core based pseudodendrimer under in vitro conditions. It exhibited 
efficient DNA condensing ability to nano-sized polyplexes (100 – 200 nm), low toxicity and 
transfection levels that were similar to high molecular weight standard PEIs like BPEI and the 
“golden standard” LPEI. Encouraging reports within recent years highlighted the great 
potential of degradable OEI derivatives35,37,79,81,106 while an improvement toward better 
defined structures was done by synthesizing pseudodendritic OEI containing structures.  
 
However, OEI is a randomly branched structure and not perfectly symmetric. For this reason 
the next step was to further improve the structural composition of pseudodendrimers toward 
more symmetric, more dendrimer-like structures as it could be achieved by the synthesis of 
PPI core based pseudodendrimers.  
 
4.3 PPI core based pseudodendrimers – a dendritic upgrade 
The structure–activity study within the OEI core based pseudodendrimers as described 
above elucidated what is structurally needed to achieve high transfection levels at low toxicity 
using pseudodendritic oligoamines: a hydrophobic core domain that has to be in an 
optimized balance to the pseudodendritic surface modification. In order to obtain a better 
defined core unit than the randomly branched OEI, the studies were extended toward 
polypropylenimine (PPI) dendrimers as core moiety. To compare influences of different 
dendrimer generations within the core unit on physicochemical and biological properties, 
generation 2 (G2) and generation 3 (G3) PPI dendrimers were grafted using HD as 
biodegradable linker. In order to define differences in terms of biophysical or biological 
activities between ethylenimine and propylenimine moieties, either OEI or PPI G2 were used 
as surface modification units. 
 
4.3.1 Improved physicochemical properties of grafted PPI core based 
pseudodendrimers 
The capability of grafted G2 and G3 core dendrimers to complex DNA was investigated using 
an ethidium bromide exclusion assay (see Fig. 22). All grafted dendrimers showed a very 
good DNA condensing ability already at low c/p-ratios if HBG (a low ionic strength buffer) 
was used for complex formation. This is in good accordance to the findings made within the 
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OEI core based pseudodendrimers where studies showed that both the hydrophobic HD core 
unit as well as a high number of nitrogens upon the pseudodendritic surface is beneficial for 
good DNA binding. However, DNA binding studies of HD O in presence of physiological 
sodium chloride concentrations revealed that its DNA binding capacity was dramatically 
reduced in presence of salt (resulting in rel.F.min of around 40%). Akin, but less pronounced 
outcomes were also found for all PPI core based pseudodendrimers (rel.F.min of 20 – 30% in 
HBS) similarly it was also found for standard polyethylenimines like LPEI (22 kDa) or BPEI 
(25 kDa) and several other polycationic gene delivery vectors.37 This indicates that the 
colloidal stability of the investigated polyplexes is obviously affected under physiological 
conditions, which is undesirable for future in vivo application of polyplexes. Some solutions 
regarding this problem topic have already been suggested43,44,74 and will also be discussed 
for the weakest of the investigated polyplexes, the HD O polyplex at a c/p-ratio of 1, in the 
last section of this thesis.   
 
To clarify in which extent the stability of grafted PPI polyplexes was improved the colloidal 
stability of complexes was investigated. For this, the susceptibility of polyplexes for 
dissociation to free DNA and polycation as a function of the amount of sodium chloride was 
determined via light scattering. Light scattering is a convenient procedure to measure 
complex formation or complex dissociation since scattered light intensity is dramatically 
increased by complex formation, especially if they aggregate, compared to free DNA and 
polycation where scattering intensity is low.66 With regard to the grafted dendrimers it was 
found that the complexes were not as susceptible to sodium chloride induced dissociation as 
compared to their unmodified counterparts (see Fig. 23). This was either demonstrated by 
the shift of the point of disassembly to higher salt concentrations and / or the minimum of 
scattering intensity. However, a significant influence of the dendrimers´ generation on the 
colloidal stability of polyplexes could only be found with regard to the unmodified dendrimers 
G2 and G3 while this effect was not as pronounced in case of the grafted compounds. 
Importantly, all the derivatives that were grafted by polypropylenimine dendrimer G2 were 
found to be less sensitive to sodium chloride induced polyplex dissociation than the OEI 
grafted ones. It can be assumed that this was due to their higher hydrophobicity caused by 
the incorporation of propylenimine (C3) instead of ethylenimine (C2) moieties upon their 
surface, resulting in lower water solubility and therefore minimizing the possibility of salt 
molecules to interfere with the electrostatic interactions between DNA and polycation. 
 
Generally, measurements of hydrodynamic diameters in HBG and HBS underlined the 
findings described above. With the presence of salt, complex sizes of grafted dendrimers did 
not change while unmodified G2 and G3 dendrimers aggregated under these conditions. 
This again indicated an improved colloidal stability of grafted dendrimers over unmodified 
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ones; hence, polyplexes of all grafted dendrimers remained stable without aggregate 
formation also in presence of physiological salt concentrations. 
4.3.2 The necessity of ethylenimine moieties for enhanced biological 
activity 
In vitro transfection studies of PPI core based dendrimers demonstrated that grafting of 
generation 2 or generation 3 core units using either polypropylenimine or oligoethylenimine 
moieties upon the surface obviously led to enhanced transfection efficiency. In preliminary 
studies (data not shown) this effect was not only found if HD was used as degradable linker 
but also if BD or ED were used.  
 
Concerning the comparison of G2 and G3 core derivatives due to influences of the 
dendrimers´ generation on transfection efficiency it can be assessed that the higher 
generation within the core unit of the derivatives did not enhance transfection efficiency in 
vitro. This demonstrates that the level of transfection is obviously limited (G2-HD-OEI ↔ 
G3-HD-OEI). It is likely that this effect can be explained by the increased stability of G3 core 
over G2 core derivatives under physiological conditions leading to a reduced intracellular 
disassembly of polyplexes. Furthermore with regard to the comparison of the different 
dendrimers´ generations, differences in the resulting cytotoxicity profile of G3 core based 
derivatives were found as compared to G2 core ones. These might be explained by the 
increased overall hydrophobicity of the polyplexes from G2 core to G3 core units causing an 
improved transfection / toxicity relation (G2-HD-G2 ↔ G3-HD-G2) which is in line with the 
results described above, i.e. likewise it was found in structure-activity studies of the OEI core 
based pseudodendrimers.18 There it was described that the balance of hydrophilic and 
hydrophobic domains within polyplexes must be optimized in order to obtain high transfection 
levels at low cytotoxicity. 
 
The higher potency of OEI grafted dendrimers over G2 grafted derivatives, as e.g. 
demonstrated by comparing G3-HD-G2 and G3-HD-OEI (see Fig. 24) may be explained by 
an enhanced endosomolytic activity based on the proton-sponge effect13,70 due to the 
incorporated oligoethylenimine moieties. In order to investigate this in more detail, luciferase 
gene transfer experiments in the absence or presence of bafilomycin A1 were performed 
(see Fig. 25). Bafilomycin A1 specifically inhibits the vacuolar type of H+-ATPases by 
blocking the endo-/lysosomal proton pump being responsible for the reported decrease of 
polyethylenimine-mediated transfection.71 The results indicated that, very similar to LPEI and 
BPEI, the OEI grafted PPI core based compounds experienced a significant decrease of 
luciferase activity in presence of bafilomycin A1 in two investigated cell lines while in contrast 
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the polypropylenimine grafted compounds were not affected. Hence, grafting PPI dendrimers 
with OEI significantly improved their transfection efficiency. Importantly, reporter gene 
expression levels were similarly high as obtained with LPEI and BPEI. Related results based 
on the incorporation of oligoethylenimine moieties upon α-cyclodextrin have been recently 
reported by Yang et al., showing that the transfection efficiency levels of their star polymers 
increased with the length and the branching degree of the OEI arms. The reported best 
transfecting polymer was modified upon the surface with an oligoethylenimine resembling 
OEI 800 Da.107 
 
Thus, the results found regarding PPI core based derivatives underline the importance of an 
optimized balance of hydrophilic and hydrophobic domains within pseudodendrimers and 
furthermore emphasize the necessity of ethylenimine moieties within conjugates in order to 
achieve highest transfection efficiency levels. Taken together, all these findings in vitro 
resulted in a couple of promising compounds for in vivo studies in mice. 
 
4.4 In vivo reporter gene expression studies of pseudodendrimers  
By structure-activity studies in vitro, it was revealed that for efficient transfection an optimized 
balance of hydrophobic and hydrophilic domains within pseudodendritic oligoamines has to 
be achieved. Hence, a couple of potent DNA gene delivering agents were defined within both 
the OEI core and the PPI core based pseudodendrimers. These most promising conjugates 
were tested for i) their biocompatibility followed by ii) investigations on their in vivo gene 
transfer activity in a subcutaneous (s.c.) tumor model after intravenous (i.v.) application of 
the polyplexes.  
 
4.4.1 Biocompatibility of polyplexes based on pseudodendrimers 
After injection of positively charged particles into the bloodstream it is likely that interactions 
with several blood components including erythrocytes occur that lead to undesired side 
effects.15 For instance, it was found that after i.v. application of LPEI polyplexes a polymer 
induced erythrocyte aggregation occurred that in some cases also resulted in lethality of 
mice; most probably due to inclusion of agglutinated erythrocytes in small capillaries of the 
lung.15 Furthermore, as an anaemic status of the patients is also not desired, hemolytic 
activity of polymers or polyplexes should be avoided and should be tested prior to an in vivo 
application. 
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In order to circumvent unexpected lethality of mice due to acute toxic side effects, the newly 
designed and most promising in vivo candidates were tested for their hemocompatibility prior 
to the study in mice. To get a rough estimate, first the degree of hemolysis of erythrocytes 
after incubation with either the plain polymers or the polyplex formulations was tested. 
Remarkably, it was detected that in all cases the trends and patterns as found in cytotoxicity 
studies were also discovered here. Hence, similar to the findings depicted in Fig. 10 and 
Fig. 11, pseudodendritic core characteristics and/or the surface modification influence 
hemolytic effects. Thus, it can be assumed that accompanied by an increasing 
hydrophobicity of the conjugate, its “intrinsic membrane activity” was also enhanced while in 
contrast more hydrophilic compounds showed no cell membrane destabilizing effect. Within 
the PPI core based pseudodendrimers the same trends emphasize these findings. 
Importantly, it was found for all pseudodendrimers that if the resulting polyplexes were 
investigated instead of the plain polymers the hemolytic activity was dramatically reduced. 
 
Although a direct correlation between the cytotoxicity of pseudodendrimers and their 
hemolytic activity can obviously be drawn, the polymer induced erythrocyte aggregation has 
to be investigated separately. As it was already shown in case of LPEI or BPEI, it cannot be 
assumed that a low hemolytic activity is also accompanied by a missing polymer induced 
erythrocyte aggregation and vice versa.15 However, according to microscopic investigations 
none of the newly synthesized polymers induced any erythrocyte aggregation. Notably, the 
investigated polymer concentrations were much higher as they would ever be applied in in 
vivo studies. Consequently, acute toxic side-effects due to agglutinated erythrocytes can 
rather be excluded for all pseudodendrimers. 
 
However, in terms of investigating the biocompatibility of novel pseudodendrimers it has to 
be kept in mind that alongside a low acute toxicity, a negligible long-term toxicity is also 
desired. Therefore, degradation studies of the most promising in vitro candidates were 
performed. It was found that all pseudodendritic oligoamines are degradable with a half-life of 
about 3 days while the best performing OEI core based conjugate HD O was obviously 
completely degradable to OEI monomers and the resulting alcohol. Furthermore, all 
degradation products were non-toxic in cell culture and did not exhibit any toxicity of Neuro2a 
cells after treatment with metabolites (data not shown). 
 
All pseudodendritic oligoamines passed the in vitro tests that were performed prior to a first 
in vivo administration. There, the acute toxicity of mice after application of 50 µg/mL polymer 
per 20 g mouse was tested. The pseudodendrimers that were interesting for further in vivo 
investigation due to encouraging in vitro transfection results were: HD S, HD O, G2-HD-OEI, 
G2-HD-G2, G3-HD-OEI and G3-HD-G2. HD O, G2-HD-OEI and G3-HD-OEI were well 
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tolerated after i.v. application of plain polymers and no acute toxic effects were found. In 
case of HD S, G2-HD-G2 and G3-HD-G2, the application of plain polymer resulted in lethality 
of mice and also as polyplex formulations those compounds were poorly tolerated. After i.v. 
administration, a pronounced vasodilatation was found in all organs, most probably due to 
the intrinsic membrane destabilization activity of the polymers as described above. 
Apparently, also if applied in a polyplex formulation, this characteristic still had a distinct 
impact under in vivo conditions in case of HD S, G2-HD-G2 and G3-HD-G2. Importantly, 
those effects were not found for any of the other pseudodendrimers. 
 
Taken together, out of all performed in vitro studies including the first in vivo toxicity study, 
three promising pseudodendritic oligoamines remained for testing their transfection efficiency 
in mice using an s.c. neuroblastoma tumor model - these were: HD O, G2-HD-OEI and 
G3-HD-OEI. 
 
4.4.2 Predominant gene expression in tumor tissue using 
pseudodendrimers 
Since HD O, G2-HD-OEI and G3-HD-OEI exhibited low acute toxicity in mice, they were 
investigated in the following studies for their in vivo gene transfer ability in tumor bearing 
mice. As references, the well investigated “golden standard” polycations LPEI and BPEI were 
used. LPEI is known to reveal highest transgene expression levels in mice with gene 
expression mainly found in the lung after i.v. application being also responsible for acute 
toxic effects.17,72 BPEI was used to compare the differences in gene expression levels 
between branched and linear high molecular weight structures. Transgene expression after 
BPEI complex application was only found in tumor, liver and lung whereas, consistent to 
previous work, BPEI led to a significantly lower gene expression in the lung than LPEI.108  
 
Mice receiving polyplexes based on pseudodendrimers showed no signs of acute toxicity 
after i.v. application, thus they were all well tolerated. With regard to the resulting transfection 
pattern found after systemic administration it can be concluded that all pseudodendritic 
oligoamines, i.e. HD O, G2-HD-OEI and G3-HD-OEI, resulted in reporter gene expression 
which was predominantly found in tumor tissue at similar high gene expression levels as the 
LPEI. Importantly, it has to be emphasized that at a c/p-ratio of 1 in all cases a much lower 
luciferase gene expression was found in the lung than in tumor tissue and negligible gene 
expression could be determined in all other investigated organs. As reporter gene expression 
levels in tumor tissue were similarly high as those obtained by LPEI, the “golden standard”, 
the finding of an increased tumor-specific reporter gene expression level after i.v. 
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administration is very worthwhile. The reasons for the differences between the transfection 
pattern of LPEI and the established pseudodendrimers remain to be clarified in detail. It 
could be suspected that due to the lack of polymer induced erythrocyte aggregation as found 
for the pseudodendrimers, they do not stick in lung or liver tissue like e.g. HMW PEIs. In 
consequence they are able to deliver the nucleic acid payload toward the tumor site due to 
most probably passive tumor targeting (“EPR-effect”)47. Nevertheless, it has to be taken into 
account and clarified that reporter gene expression level may not be in direct correlation to 
the body distribution pattern, as previously described.51,109 Thus, in the current case, positive 
charges of polyplexes cannot be the sole explanation for the observed gene expression 
patterns since all polyplexes of pseudodendrimers at c/p-ratio 2 still showed a more 
favorable tumor / lung relation as compared to LPEI, although best tumor / lung ratios (T/L) 
were obtained when using c/p-ratio 1. 
 
Furthermore, the study within PPI core based pseudodendrimers demonstrated a clear 
influence of the dendrimer generation within the conjugates upon transfection efficiency in 
vivo. For G3-HD-OEI polyplexes, gene expression levels in tumor tissue were 12-fold higher 
(p < 0.05) as compared to G2-HD-OEI at c/p-ratio 1. It can be hypothesized that this effect is 
either due to the better biophysical properties and improved colloidal stability of G3-HD-OEI 
vs. G2-HD-OEI, or due to the increase of positive charges of the polyplexes, or a 
combination of both factors. 
 
HD O, G2-HD-OEI and G3-HD-OEI were all well tolerated by mice and no significant loss of 
body weight was observed if a c/p-ratio of 1 was applied (5 – 6% BWL after 24 h) 
Histopathologic investigations on liver tissue (HD O; see Fig. 20) underline the findings, 
since no changes in liver histology compared to buffer treated mice have been found as well 
as no increase of liver enzyme levels (AST, ALT and AP) were detectable. The same was 
shown after application of polyplexes using the PPI core based pseudodendrimer (see 
Fig. 19 and Fig. 29). In contrast to this, LPEI and BPEI complexes always resulted in an 
increase of liver enzyme levels indicating beginning necrotic changes in liver tissue already 
after 24 h, which is consistent with literature and as demonstrated in Fig. 20.17,110 The 
reasons for the better in vivo tolerability of the pseudodendritic polyplexes may be explained 
besides their degradability and good biocompatibility as described above due to obvious 
structural differences including the lower molecular weight compared to standard LPEI or 
BPEI. Within the PEI class of polymers, a lower molecular weight has previously been found 
to provide better biocompatibility.111,112 
 
All in all, these in vivo studies reveal that plain pseudodendrimer / DNA polyplexes (without 
further functional modifications) have the potential for an increased specific transfection of 
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tumor tissue at levels comparable to those of LPEI and exhibit significantly reduced 
transgene expression in the lung (T/L-ratio (G3-HD-OEI): 89 vs. T/L-ratio (LPEI): 0.01 – 
0.001). Moreover, all the investigated pseudodendrimers were well tolerated by mice 
exposing best biocompatibility properties.18  
4.5 Optimization of polyplexes toward “synthetic viruses” 
As the success of gene therapy is highly dependent on the delivery system, research has 
focused on the development of gene transfer devices suitable for highly potent systemic 
nucleic acid delivery. Although many polymeric carriers have been optimized in vitro to 
overcome several cellular hurdles, there are many barriers that have to be resolved in order 
to achieve successful, i.e. long-lasting and highly efficient, in vivo gene delivery. 
Unfortunately, most of the existing vectors are currently – independent of their toxicity profile 
– unsuitable for systemic administration due to rapid elimination from the bloodstream 
combined with unspecific interaction with and accumulation of particles in organs and 
tissue.15,74,113,114 Investigations to reduce those effects, e.g. by using steric stabilization 
procedures (PEGylation) to create so called “stealth vectors”, were extensively performed in 
order to achieve long-circulating polyplexes, thereby reducing additional unspecific 
interactions with non-target sites. However, in these studies it was also found that it is likely 
that this strategy in some cases also leads to labile polyplexes under physiological 
conditions, resulting in disruption of the polycation / DNA particles due to reorganization of 
the polyplexes caused by protein interaction or high salt concentrations.42  
 
Several groups reported for the last years that they countered this by successfully increasing 
polyplex stability by e.g. lateral stabilization of particles.43,44,68,73,74 Therefore, the surface 
molecules of polyplexes were crosslinked in order to prevent their dissociation. Furthermore, 
stabilized polyplexes may offer an attractive stable platform for subsequent modifications. 
 
4.5.1 Lateral stabilization for improved gene expression of HD O 
polyplexes 
Taking into account that the polymers developed in this thesis resulted in LMW polycations 
which also exhibited a lower charge density compared to HMW polycations like e.g. BPEI, it 
could be assumed that their colloidal stability under physiological conditions is reduced. 
Similar effects were already demonstrated for PLL polymers.26 In fact, in pilot studies a 
decreased colloidal stability under physiological conditions was found for HD O / DNA 
complexes at a c/p-ratio of 1. Hence, as a first step toward an improved formulation for 
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systemic administration, the stability of HD O polyplexes was increased by employing a 
lateral stabilization strategy. Nevertheless, it has to be kept in mind that the gained stability of 
those complexes may present a double-edged sword: since the extracellular stability of the 
polyplexes is beneficial with regard to their pharmacokinetic properties on the one hand, the 
undesired rigidity in intracellular environment on the other hand may result in a decreased 
unpackaging ability of DNA leading to lower transfection efficiency levels. To overcome this 
discrepancy, the bioreducible crosslinker DSP was used for polyplex stabilization in these 
studies. Its stable counterpart DSS was used as control. DSP as linking reagent, but not 
DSS, was recently also used by Neu and colleagues44 comparing lateral stabilization of LMW 
and HMW PEI polyplexes. Unlike their findings regarding stabilized LMW PEIs, HD O 
polyplexes did not result in aggregation after crosslinking. Presumably, a tighter polyplex 
structure of HD O complexes was already obtained prior to crosslinking them upon the 
surface. This effect might be attributed to the presence of the hydrophobic moieties within 
HD O, resulting in a more compact DNA binding due to an increase of hydrophobic 
interactions between polymer and DNA. Thereby, the possibility to destroy electrostatic 
interactions between DNA and polycation was minimized. Both crosslinkers (DSP and DSS) 
at optimized linking degrees did not affect general physicochemical properties of HD O 
(mean diameter and zeta-potential of particles) but showed that by lateral stabilization the 
susceptibility of polyplexes against either “competitive” polyanions like heparin (see Fig. 32) 
or high salt concentrations (see Fig. 34 and Fig. 35) was decreased. However, unlike found 
for BPEI, the transfection efficiency levels under in vitro conditions did not significantly differ 
between the bioreducible DSP and the non-reducible DSS linker. As HD O, in contrast to 
BPEI, possesses hydrolysable ester bonds, it is likely that the bioreducibility of the disulfide 
bonds is largely evened out by the simultaneous degradation of the ester bonds. 
Furthermore, it was found in several cell lines that only if DSP was used for lateral 
stabilization of HD O complexes, the transfection efficiency levels were raised to the same or 
even higher reporter gene expression levels as detected for the unstabilized polyplexes. In 
comparison, the DSS-linked particles resulted in a 5- to 10-fold lower gene expression level. 
Hence, it can be concluded that the reversibly DSP-linked hydrolyzable HD O / DNA 
polyplexes exhibited an optimized balance of extracellular stability and intracellular instability 
maintaining high transfection efficiency while no cytotoxic effects were found.  
 
Recent in vivo studies involving investigations of laterally stabilized polyplexes based on 
HMW polycations like e.g. BPEI or PLL revealed that after i.v. administration of those 
polyplexes, increased blood concentrations were found compared to unstabilized 
particles.43,68,74 By this, Oupicky et al.74 elucidated the importance of bifunctional stabilization 
in comparison to monovalent modification of polyplex surfaces for systemic administration. 
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Neu and colleagues emphasized furthermore the alteration of organ specific reporter gene 
expression after i.v. administration of DSP-crosslinked BPEI polyplexes.68 However, none of 
the studies described an efficient in vivo gene delivery strategy using crosslinked 
biodegradable LMW polycations to date. Investigations on the effects due to lateral 
stabilization of the presumably rather susceptible HD O particles were important in terms of 
improving its in vivo profile for further investigations in mice. Notably, after intratumoral 
application of DSS, DSP or uncrosslinked HD O polyplexes two interesting and encouraging 
points were found: first, reporter gene expression levels of stabilized polyplexes were 
significantly higher compared to uncrosslinked polyplexes (4-fold; p < 0.001). And secondly, 
only for the stabilized polyplexes, a permanent and similar high reporter gene expression in 
tumor tissue was found over time (4 days), while DSP mediated levels were always superior 
to DSS ones. Presumably, polyplex destabilization by reductive cleavage of DSP was 
boosted by the alongside hydrolytic degradation of HD O resulting in a more efficient release 
of the nucleic acid payload as compared to DSS resulting in better gene expression. In 
contrast, uncrosslinked HD O polyplexes resulted in step by step decreasing reporter gene 
expression levels over time. Noteworthy, similar results were also detected in in vitro results. 
Nevertheless, it is evident that lateral stabilization of LMW polyplexes is essential for 
prolonged reporter gene expression. 
 
To sum it up, it can be assessed that lateral stabilization of vectors based on LMW 
degradable polyplexes may provide a promising strategy to improve their pharmacokinetic 
properties, especially regarding further in vivo applications. Moreover, the previously rather 
susceptible HD O polyplexes resulted in more stable particles under physiological conditions 
and due to this they offer an interesting platform for further modifications, e.g. with targeting 
ligands. 
 
4.5.2 Tf-targeting of stabilized HD O polyplexes – an outlook toward 
synthetic viruses 
Various methods have been investigated in the past to achieve high specificity for the tumor 
as target as it is desired for clinical applications in cancer gene therapy. Targeting strategies 
include directed delivery of polyplexes to the target site as well as transductional and 
transcriptional targeting policies involving the intracellular fate of the particles (see Fig. 4). 
Besides biological targeting strategies also physical practices or a combination of both have 
been applied and showed encouraging results in several studies.57,59,75,115-118 
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Here, the transferrin receptor (TfR) was selected as cell surface target since it is over-
expressed in a variety of tumor cells because of their higher demand of iron, needed for their 
fast growth.49 Moreover, transferrin (Tf) as protein ligand combines both a shielding function 
of the polyplexes (reducing unspecific interactions e.g. with erythrocytes15) and a targeting 
moiety toward the tumor site.50,51 The incorporation of Tf as targeting ligand into polyplexes 
based on LMW pseudodendritic oligoamines to increase their delivering specificity might be a 
further step toward the design of more virus-like and biodegradable synthetic systems. 
Although pseudodendritic oligoamines, as investigated here, already resulted in a 
predominant reporter gene expression in tumor tissue after i.v. administration, it is most likely 
that their biodistribution pattern differs from their gene expression pattern.109,119 Hence, 
directing polyplexes, at best, exclusively toward the tumor site might be beneficial in order to 
reduce undesired accumulation of complexes at non-target sites.  
 
Because HD O polyplexes at a c/p-ratio of 1 resulted, by either mixing the targeting ligand 
with the polyplexes or following a standard procedure for Tf incorporation by Tf-BPEI, in 
extensive aggregation, it was obvious that under these conditions a suitable vector 
formulation was not amenable. Hence, the lateral stabilization technology as established and 
evaluated above was essential for the incorporation of a targeting moiety. Due to their 
bioreducibility and most promising in vitro and in vivo results, DSP-crosslinked particles were 
utilized in the following studies for TfR targeting. It can be assumed that due to the deficiency 
of crosslinker used for efficient polyplex stabilization, no residual free linker was left while a 
number of primary amine bonds remained upon the surface of particles (zeta-potentials after 
crosslink did not significantly decrease). Those can be used for formation of Tf-coated 
vectors. In the described studies the oxidized form Tfox was investigated to form meta-stable 
imine bonds between primary amines upon the particle surface and the aldehyde 
functionality of Tfox. The unoxidized form of transferrin (Tfunox) was studied for comparison in 
order to exclude unspecific effects. Generally, it is hypothesized that the efficient Tf-coating 
of particles using the described vector formulation only happens in case of Tfox. There, the 
incorporation of Tf onto polyplexes by hydrolysable imine bonds was assumed to be stable 
enough due to the presence of multiple amines in the polyplex. 
 
Physicochemical examinations showed that already a very low amount of 3.5% [w/w] Tf was 
sufficient to form small (180 – 200 nm) complexes reducing the zeta-potential from +30 mV 
to +14 mV in case of Tfox. This already indicates a shielding effect due to effective coating of 
the particles. The decrease of the zeta-potential using Tfunox was less pronounced (to 
+23 mV) indicating a less sufficient covering by transferrin since no imine bond can be 
formed. Only stabilized particles involving a DSP/HD O-ratio of 0.05 and 0.06 were suitable 
for Tf-coating while ratio 0.07 resulted in aggregation after addition of 3.5% Tfox or Tfunox. 
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Investigations of the resulting Tf-polyplexes showed in vitro in both studied cell lines - 
Neuro2a and K562 cells, the same transfection pattern. Only the Tfox coated particles showed 
an up to 10-fold increased reporter gene expression level, whereas particles covered with 
Tfunox remained at the same level as unstabilized, targeted HD O polyplexes. This points out 
that obviously only the formulation with oxidized transferrin is able to lead to enhanced 
reporter gene expression.  
Hence, also in these studies the importance of an increased extracellular stability of the 
polyplex formulation, which has to be in an optimized balance to a triggered instability of the 
particle, was demonstrated. The combination of both characteristics (extracellular stability 
and triggerable destabilization) within targeted, bioresponsively stabilized HD O complexes 
presents a prototype for synthetic virus-like polyplexes, which undergo programmed 
structural changes compatible with the different gene delivery stages, “sensing” the biological 
(micro-) environment.  
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5 Summary 
Gene therapy offers a promising tool for treating various diseases including cancer and a 
number of inherent disorders. The clinical use is still restricted mainly due to the lack of safe 
and efficient gene delivery systems. Recent investigations increasingly focus on synthetic 
gene carriers as alternatives to viral vectors mainly due to their better bio-safety. 
Furthermore, these gene transfer devices might be advantageous in terms of pharmaceutical 
issues such as low cost of synthesis and easy scale-up. 
 
In the course of this thesis, the design and establishment of a novel family of hyperbranched 
degradable polymers, named pseudodendrimers, is reported. These structures are formed 
step by step in a dendritic concept by adding several monomeric moieties upon a central 
core unit via – in the present case – hydrolysable branches. The pseudodendritic synthesis 
concept, the analysis of the structural composition of the resulting polycations and the 
investigation of their physicochemical properties as well as biological characteristics are 
reported. Studies on DNA binding ability, polyplex stability, cytotoxicity and transfection 
efficiency demonstrated that pseudodendritic core characteristics as well as the surface 
modifications among the pseudodendritic core influence both transfection efficiency and 
cytotoxicity in vitro. At first, it was elucidated that a hydrophobic core moiety is essential for 
potent gene delivery. In the current case only HD core conjugates (C6 spacer) led to efficient 
gene transfer. BD and ED core compounds with a C4 and C2 spacer, respectively, resulted 
in stepwise decreasing transfection efficiency as the intrinsic membrane destabilizing effect 
was simultaneously diminished. Furthermore, in these structure-activity relationship studies it 
became evident that the surface modification has to be optimized relative to the core unit that 
should finally result in a perfect balance of hydrophilic and hydrophobic domains within the 
pseudodendrimer in order to obtain highest transfection efficiency at low cytotoxicity. Most 
importantly, in studies within the structurally better defined PPI core based 
pseudodendrimers it was clarified that ethylenimine moieties within the compounds are 
essential to improve the transfection efficiency (“proton sponge effect”). A couple of the novel 
gene carriers that followed the prerequisites mentioned above were successfully applied in in 
vitro transfection studies where they easily competed with the “golden standard” linear 
polyethylenimine 22 kDa (LPEI). 
 
Out of the described structure-activity studies, the six most promising conjugates were 
investigated for their in vivo gene transfer efficiency in a subcutaneous tumor model in mice. 
Prior to systemic application, investigations regarding their biocompatibility were performed 
including in vitro studies on polymer degradation kinetics and their hemocompatibility and 
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first in vivo testings on acute toxicity after i.v. application of plain polymer in mice. All these 
studies revealed that only three pseudodendrimers remained for further in vivo 
administration: HD O, G2-HD-OEI and G3-HD-OEI. Notably, all these polymers had a 
degradation half-life of about 3 days, induced no erythrocyte aggregation and were well 
tolerated by mice even if applied as plain polymer.  
 
In vivo studies in mice that were bearing subcutaneous neuroblastoma tumors exhibited that 
DNA polyplexes of all three compounds upon intravenous tail vein injection had the potential 
for transfection of tumor tissue at levels comparable to those obtained with LPEI. Importantly, 
all pseudodendrimers were better tolerated than LPEI while transgene expression was more 
tumor-specific and much lower in all other investigated organs, especially in the lung (e.g. 
T/L-ratio (HD O) = 20; T/L-ratio (G3-HD-OEI) = 89). A clear influence of the dendrimers´ 
generation used within the core unit on transfection efficiency was found resulting in 
significantly (p < 0.05) higher reporter gene expression if generation 3 was used instead of 
generation 2, which was demonstrated within the PPI core based pseudodendrimers.  
 
As the success of gene therapy is highly dependent on the delivery system, research has 
focused on the development of gene transfer devices suitable for highly potent and specific 
systemic nucleic acid delivery. Compared to their viral counterparts, current synthetic vectors 
are still very inefficient, suffering from rapid elimination from the bloodstream combined with 
unspecific interaction with and accumulation of particles in organs and tissue. In order to 
optimize the described LMW degradable vectors toward “synthetic viruses” two approaches 
were followed. First, particles were laterally stabilized via bioresponsive crosslinkers in order 
to avoid extracellular disassembly of polyplexes followed by rapid elimination and 
subsequent decreased reporter gene expression levels under physiological conditions. 
Hence, it was demonstrated here that crosslinking polyplexes via a disulfide containing linker 
system (DSP) resulted in increased and prolonged transfection efficiency both under in vitro 
and in vivo conditions. The second optimizing step comprised the incorporation of transferrin 
(Tf) as site-specific targeting ligand upon the stabilized particles. In vitro studies 
demonstrated that vectors – if coated with Tfox via oxidized carbohydrate-imine linkages – 
resulted in up to 10-fold enhanced transfection efficiency levels. With regard to in vivo 
application, this polyplex formulation provides the opportunity to increase on the one hand 
the possibility of an increased site-specific delivery and on the other hand the potential to 
reduce unspecific interactions with non-target sites. 
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6 Appendix 
6.1 Abbreviations 
ALT   alkaline aminotransaminase 
AP   alkaline phosphatase 
AST   aspartate aminotransaminase 
BD   1.4-butandioldiacrylate 
BPEI   branched polyethylenimine of a Mw of 25 kDa 
BWL   body weight loss 
CMV   cytomegalovirus 
c/p-ratio  weight ratio of conjugate to plasmid  
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMSO   dimethyl sulfoxide 
DNA   deoxyribonucleic acid 
DSP   dithiobis (succinimidylpropionate) 
DSS   disuccinimidyl suberate 
DTT   dithiothreitol 
E   ethanolamine 
ED 1.2-ethyleneglycoldiacrylate 
EDA ethylendiamine 
EPR enhanced permeation and retention 
EtBr ethidium bromide 
FCS fetal calf serum 
GPC gel permeation chromatography 
HBG HEPES-buffered glucose 
HBS HEPES-buffered saline 
HD 1.6-hexandioldiacrylate 
HEPES N-(2-hydroxyethyl) piperazine-N’-(2-ethansulfonic acid) 
HMW high molecular weight 
GLDH glutamate dehydrogenase  
i.v. intravenous 
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i.p. intraperitoneal 
i.t. intratumoral 
LMW low molecular weight 
LPEI linear polyethylenimine of a Mw of 22 kDa 
MTT methylthiazoletetrazolium 
Mw weight average molecular weight 
Mn number average molecular weight 
MQ deionized water (Millipore) 
1H NMR nuclear magnetic resonance 
N/P-ratio molar ratio of PEI nitrogen to DNA phosphate 
OEI oligoethylenimine 800 Da 
PEHI pentaethylenheximine 
PDI polydispersity index 
RLU relative light units 
S spermine 
Sp spermidine 
TETA triethylentetramine 
Tf transferrin 
Tf-BPEI transferrin covalently attached to BPEI  
Tfox oxidized transferrin 
Tfunox unoxidized transferrin 
T/L tumor / lung-ratio 
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6.2 Publications 
6.2.1 Original papers 
• Russ, V., Elfberg, H., Thoma, C., Kloeckner, J., Ogris, M., Wagner, E. (2008): 
Novel degradable oligoethylenimine-acrylate ester-based pseudodendrimers for in 
vitro and in vivo gene transfer. Gene Ther. 2008 Jan; 15(1):18-29.  
 
• Knorr, V., Russ, V., Allmendinger, L., Ogris, M., Wagner, E.: Acetal linked 
oligoethylenimines for use as pH-sensitive gene vectors. Bioconjug Chem. 2008 
Aug; 19(8):1625-34. Epub 2008 Jul 16 
 
• Russ, V., Günther, M., Halama, A., Ogris, M., Wagner E.: Oligoethylenimine-
grafted polypropylenimine dendrimers as degradable and biocompatible synthetic 
vectors for in vitro and in vivo gene delivery. J Control Release. 2008 Sep 10. 
Epub ahead of print 
 
 
6.2.2 Manuscripts in preparation 
• Russ, V., Halama, A., Ogris, M., Wagner, E.: Importance of lateral bioreversible 
stabilization of LMW polyplexes. In preparation. 
 
• Yu, H.*, Russ, V.*, Wagner, E.: High Efficient Synthetic Gene Vectors Based on 
Bioreducible PEI. In preparation. 
 
• Klutz, K.*, Russ, V.*, Willhauck, M.J., Wunderlich, N., Zach, C., Münzing, W.,  
Gildehaus, F.J., Göke, B., Wagner, E., Ogris, M., Spitzweg, Ch.: Tumor-specific 
iodide uptake activity in neuroblastoma tumors following systemic sodium iodide 
symporter gene transfer using synthetic gene delivery vectors. In preparation. 
 
6.2.3 Reviews 
• Russ, V., Wagner, E. (2007) Cell and tissue targeting of nucleic acids for cancer 
gene therapy. Pharm Res. 2007 Jun; 24(6):1047-57. 
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6.2.4 Poster presentations 
• Verena Russ, Manfred Ogris and Ernst Wagner: Toward artificial viruses: novel 
biodegradable gene carriers based on pseudodenritic oligoamines, VIU, 2006, 
Venice, Italy 
 
• Julia Fahrmeir, Anita Bogomilova, Verena Russ, Neli Koseva, Manfred Ogris, 
Kolio Troev and Ernst Wagner: Novel Biodegradable Gene Carriers based on 
Polyphosphoramidates, 33rd annual meeting & exposition of CRS, 2006, Vienna, 
Austria 
 
• Kathrin Klutz*, Verena Russ*, Michael J Willhauck, Nathalie Wunderlich, Christian 
Zach, Wolfgang Münzing, Franz Josef Gildehaus, Burkhard Göke, Ernst Wagner, 
Manfred Ogris, Christine Spitzweg: Tumor-specific iodide uptake activity in 
neuroblastoma tumors following systemic sodium iodide symporter gene transfer 
using synthetic gene delivery vectors, 15th Annual Meeting of the German Society 
of Gene Therapy, 2008, Berlin, Germany 
 
• Terese Magnusson, Verena Russ, Isabella Stapff, Rudolf Haase, Armin Baiker, 
Ernst Wagner, Manfred Ogris: Optimising nonviral ex vivo transferrin mediated 
transfection of the erythroleukemia cell line K562 with episomal vectors, 15th 
Annual Meeting of the German Society of Gene Therapy, 2008, Berlin, Germany 
 
6.2.5 Oral presentations 
• Kathrin Klutz, Verena Russ, Michael J Willhauck, Nathalie Wunderlich, Christian 
Zach, Wolfgang Münzing, Franz Josef Gildehaus, Burkhard Göke, Ernst Wagner, 
Manfred Ogris, Christine Spitzweg: Tumor-specific iodide uptake activity in 
neuroblastoma tumors following systemic sodium iodide symporter gene transfer 
using synthetic gene delivery vectors, ENDO 2008, San Francisco, USA 
 
• Verena Russ, Manfred Ogris and Ernst Wagner: Efficient gene transfer with a 
novel degradable pseudodendritic oligoamine: an in vitro and in vivo study; ASGT 
10th Annual Meeting, Seattle, USA, 03.06.2007 
 
• Verena Russ, Julia Kloeckner, Manfred Ogris and Ernst Wagner: Novel 
biodegradable gene carriers based on pseudodendritic oligoamines; 33rd annual 
meeting & exposition of CRS, Vienna, Austria, 25.07.2006 
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